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CHAPTER 1 “DENDRIMERS FOR OCULAR DRUG DELIVERY” 
1.1. Ocular drug delivery- Importance and challenges 
Blindness is a leading health care issue (after cancer) worldwide, with important socio-
economic consequences. According to World Health Organization (WHO) more than 314 
million people age 40 or older visually impaired due to age related eye diseases such as Age 
Related Macular Degeneration (AMD), Choroidal neovascularization (CNV), Diabetic 
retinopathy, Retinitis pigmentosa (RP), Glaucoma, Central vein occlusion and Intra ocular 
tumors, uveits and cataracts [1]. It is expected to dramatically increase from 28 million today to 
43 million by the year 2020 in US population [2]. Blindness and irreversible sight impairment 
cost $50 billion in the United States. The commercial ophthalmic market is estimated to be $14 
billion in 2009 and it is expected to reach $19 billion by end of 2014 [3]. Drugs are being used 
for treating these ocular diseases by conventional routes such as topical and systemic. Topical 
applications are mostly used for treating anterior segment related diseases. Mostly Anti-
inflammatory (corticosteroids), Steroids, Anti-fungal (imidizoles, polyenes), Antibiotics, Miotics 
etc are being used in the form of liquid formulations via topical route for treating various 
diseases associated with anterior chamber [4, 5]. These drugs have delayed permeability through 
intact corneal epithelium [6, 7] and due to this reason they do not  remain for prolonged time and 
are susceptible to be washed out by tear (30 s) or occurrence of drug – protein binding in tear 
fluid. 90% of these drugs are diluted and washed by lachrymal gland secretion and its 
nasolachrimal drainage. Some percentage of drugs is lost by tear dilution and tear turnover and 
typically less than 5% of the total administered drug reaches the aqueous humor by crossing the 
pre-corneal and corneal barriers ( epithelium, stroma and endothelial tight junctions) [8, 9]. In 
order to maintain and deliver therapeutic concentration to the target site, repeated dosage is 
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adopted which results in poor patient compliance. Due to low ocular bioavailability invasive 
methods like peribulbar, Sub-tendon, Sub-conjunctival injections are used. Drug delivery to 
posterior segments was previously by systemic dosage but major drawback is that only 2% of the 
injected drug reaches the vitreous cavity due to the blood retinal barrier selective permeability 
and drug metabolization in systemic route. Hence frequent administration of high amounts of 
drugs results in systemic side effects [10]. Intraocular injections such as Intravitreal, 
suprachoridal and retrobulbar methods are used [11]. Since intravitreal injections offers high 
concentrations of drugs in vitreous cavity and retina leads to accumulation and side effects which 
results in retinal detachment, endophthalmitis and intravitreal hemorrhages. Implantable devices 
can be used for sustained delivery of drugs. There are different types of implantable devices 
based on their location such as reservoir free floating implants - Medidur (Alimera Sciences, 
USA and pSivida Inc.,USA) and Posurdex (Allergan Inc., USA) , Intrascleral - Surodex 
(Allergan Inc., USA) , intravitreal paras-planar mediated implants - Retisert (Bausch & Lomb, 
Rochester, USA) and Vitrasert (Bausch & Lomb, Rochester, USA), Scleral plugs - Surmodics 
Inc. (Eden Prairie, MN) and PLGA (Biodegradable scleral plugs). Some of these implants needs 
minor surgery for implantation and requires another surgery for surgery to harvest the device 
once is depleted of the drug; these surgeries are associated with ocular complications such 
infections at implant site, inflammations and tissue rejections. In case of biodegradable Implants 
final uncontrolled burst drug release profile which results in side effects. 
Since the above ocular drug delivery systems have disadvantages, optimum ocular drug 
delivery systems should be developed such that they satisfy the following parameters 
• Control over drug release kinetics (sustained release is preferred). 
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• Should enhance drug permeation in to the cells (crossing of blood retinal barriers). 
• Targeting drug to the required specific areas of ocular tissue. 
• Patient compliance, low irritation, bioavailability and compatible. Ocular diseases such 
cataracts, The critical need to fight blindness is also aided by the large commercial ophthalmic 
market, which together can be a powerful driving force for clinical translation of novel 
nanotechnology-based drug delivery approaches. 
Biocompatible Particulates (microparticles and nanoparticles) are being investigated in all 
systems such as Central nervous systems, Respiratory, Cardiovascular, digestive, etc.  Recent 
years there is an unprecedented growth of investigating various nanoparticles in field of drug 
delivery because of their controllable surface chemistry, easy formulations, small size, increased 
surface stability and increased surface area which helps in drug targeting, reduced toxicity, 
increases drug stability and provide more efficient drug distribution. 
1.2.  Anatomy of the eye – A special reference to ocular barriers: 
“Eye is deemed to be a unique organ of extreme perfection and complication” – as a whole it 
appears to be simple, small and transparent with three tunics the fibrous corneo-sclera, vascular 
choroid and sensory retina. The eye ball is divided in to two segments (i) anterior segment 
containing cornea, crystalline lens, iris, ciliary body and fluid filled aqueous humor. (ii) Posterior 
segment includes sclera, choroid vessels, retina, macula, optic nerve and fluid filled vitreous 
humor [12]. The actual complexity arises when probed in to micro anatomy, physiology and 
biochemical perspective. The tunics are highly complex structures arranged with descending 
degree of light transparency that transverses light to retina where the photo signals are converted 
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to electrical signals and transmitted to higher centers of the brain. This organ is well protected 
 
Figure 1:  A schematic representation of critical ocular barriers that offers challenge to ocular drug delivery. A) Tear film 
barrier: A protective barrier of tear film contains mucins that prevent foreign materials coming in contact with corneal 
epithelium. They are frequently washed away via lachrymal drainage to remove entrapped materials B) Corneal barrier: 
consisting of 4-5 epithelial layers fused together by tight junctions preventing entry of particles followed by thick stroma and 
endothelial cells. C) Blood-Retinal barrier (BRB) consisting of Inner BRB formed by retinal capillaries. The endothelial cells 
fused together by tight junctions impeding outward passage of foreign materials, toxins and proteins. Outer BRB  formed by the 
tight junctions between RPE, making retina impervious but allowing oxygen and other nutrients diffuse through them. 
 
with various specialized cellular modifications that maintain its normal physiology and structure 
[13]. Moreover these modified cellular structures gives rise to various barriers that partially 
isolates the eye from rest of the body [14]. These special processes consists of the (i) inner and 
outer Blood Retinal Barriers (BRB) in retinal blood vessels and tight junctions of retinal pigment 
epithelium (RPE) respectively separates the retina from systemic circulation and avoids entry of 
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unnecessary components into retina, (ii) Barrier formed by fusion of Müller cells in the Inner 
limiting membrane (ILM) controls the exchange and entry of particles from vitreous to retina, 
(iii) Blood-aqueous barrier formed by cilia epithelial cells limits the passage of molecules from 
blood to inner part of eye, (iv) blood vessels of iris lack fenestrations, (v) intact corneal 
epithelium with desmosomes as an outer barrier and corneal endothelium abundant with tight 
junctions as inner corneal barrier, (vi) Muco-aqueous barrier formed by the tear film prevents 
and continuously washes away the particles at anterior surface of eye [14, 15]. A schematic 
diagram of structure of eye with all the ocular barriers are illustrated in Figure 1. 
1.3. PAMAM dendrimers – physiochemical characteristics and biomedical applications 
Dendrimers are globular, nanostructured polymers (~ 3-20 nm) with a well-defined shape, 
narrow polydispersity. Polyamido amine (PAMAM) (Figure 2) were first synthesized by tomalia 
[16] and it was the first commercialized dendrimers in dendrimer family and are promising drug 
delivery vehicles because of their multivalency, well-defined and globular structure, low 
polydispersity, and amenability to post-synthetic manipulation that are extensively investigated 
for various biomedical applications [17]. PAMAM dendrimers have ethylene diamine (EDA) 
core and an amidoamine repeat branching structure. They are synthesized via Michael addition 
of amino groups of EDA with methyl acrylate, followed by amidation of the resulting esters with 
EDA, and generation 0 is formed (Figure 2). A repetition of these two synthetic steps adds 
another layer of branching units and produces next generation. The size of dendrimer grows 
linearly in diameter as a function of added generations, approximately 1 nm per generation. Each 
new generation also doubles the number of terminal groups and approximately doubles the 
molecular weight of the previous generation. Figure 4 shows the synthesis of amine (NH2) 
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terminated PAMAM dendrimers that are cationic; however there is also neutral hydroxyl (OH) 
and anionic carboxyl (COOH) terminated PAMAM dendrimers. 
Figure 2:  Synthesis of PAMAM dendrimers by Tomalia [17], and a schematic structure of fully synthesized 
generation 4 (G4) dendrimer with hydroxyl (OH), amine (NH2) or carboxyl (COOH) end groups. 
 
Properties those are beneficial for drug delivery: 
1) Appropriate size: The size of these nanoparticles is a major positive property that makes 
dendrimers idle to work with in terms of conjugation chemistry, ease for characterization 
and in biological aspect they can give desired cellular internalization, biodistribution and 
effective clearance. Dendrimers have different size based on different generations from 
G2-G10. For example in the case of Generation 4 dendrimer the size ranges from 4-5nm 
makes it idle for crossing biological barriers.  
2) Branching structure: They have exceptional structural properties such as branching, 
multiple surface functional groups that make them highly amenable for various 
chemistries such as conjugation of multiple copies of single or multiple drugs, targeting 
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ligands thereby providing high pay load. Their multivalency also makes them suitable for 
complex with therapeutic genes for their safe delivery to the targeted cells. The multiple 
surface groups also provide an additional feature and opportunity for high crosslinking 
densities with short polymers and are suitable designing tissue engineering scaffolds with 
desirable mechanical strengths, sealants and hydrogels for wound healing and depot 
release drug delivery. 
3) Composition: The composition of dendrimer makeup is also an important criterion as it 
determines the biocompatibility nature of these nanostructures. PAMAM dendrimers are 
made up of subunits that have chemical structure similar to amino acid β-Alanine. 
Moreover dendrimers behave as protein molecules by exhibiting active conformational 
changes at different pH environments.  Generation 4 PAMAM dendrimer has size 
comparable to cytochrome-C (4 nm), generation 5 PAMAM dendrimer has size 
comparable to hemoglobin (5 nm), and so on [18]. Conformation of dendrimers strictly 
depends on pH. At low pH (~3), all primary amine groups of PAMAM dendrimers are 
protonated leading to an extended conformation due to electrostatic repulsion between 
the positively charged NH3 + groups. At neutral pH back folding occurs which is due to 
the hydrogen bonding between the uncharged tertiary amines in the interior and the 
positively charged surface amines. At basic pH the dendrimer is completely neutralized 
and repulsive interactions between the wedges and end-groups reach a minimum leading 
to a conformation with a higher degree of back folding so dendrimer acquires a more 
spherical (globular) structure. The conformation of dendrimers is also affected by the 
polarity of the solvent as well as the ionic strength (high concentration of salts) [18]. 
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Figure 3:  A diagrammatic representation of the versatility of the dendrimer structure that enables tailorability. A) 
Dendrimers as drug delivery vehicles where drug molecules and targeting moieties can be covalently linked to 
surface groups. B) Dendrimers as carriers of contrast agents for MRI and fluorescent imaging. C) Dendrimers as 
gene delivery vehicles where genes such as mRNA, siRNA, or DNA can be complexed. D) Surface modification of 
dendrimer surface with short mucoadhesive and bioactive polymers to enhance their activity or to increase their 
circulation time.  
 
4) Surface charge: The surface charge (zeta potential) of dendrimers is also an important 
factor as it determines the cellular entry and various biological interactions with the extra 
cellular matrix (ECM), proteins and enzymes. For example, hydroxyl dendrimers (G4-
OH) have a surface charge of ~ +4.0mV due to the internal amines and there is a perfect 
balance between the amine and hydroxyl groups in terms of charge and it is suitable for 
cellular entry. The amine terminated dendrimer (G4-NH2) has a surface charge of +16.0 
mV and have susceptible for plasma proteins, and cell membrane interactions. On other 
hand Carboxyl terminated dendrimers (G3.5-COOH) has negative surface charge that can 
help avoid un-necessary interactions that can delay or inhibit targeted delivery of 
therapeutic agents. All the above characteristics make dendrimers versatile and suitable 
for biomedical applications. Figure 3 illustrates the versatility of PAMAM dendrimers 
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and a schematic representation of conformational changes due to their external 
environment [19]. 
 
1.4.   Dendrimers for Ocular drug delivery: Advantages   
1) Corneal Permeation enhancers & improved drug delivery: Polyamidoamine 
(PAMAM) dendrimers can have different cell entry pathways, depending on the surface 
functionality. Anionic PAMAM dendrimers are endocytosed primarily through a 
caveolin-mediated process, whereas neutral and cationic dendrimers were reported to 
follow clathrin-mediated internalization in cells [20, 28]. These cellular internalization 
processes can be highly beneficial in the case of crossing the epithelial and retinal 
barriers in cornea and retina. PAMAM dendrimers showed remarkable interactions with 
membrane-associated mucin layers. Surface plasmon resonance (SPR) was used to probe 
the interfacial interactions between dendrimer surfaces and ocular mucins at the 
molecular levels [21]. For example dendrimer formulation in the form of eye drops 
showed improved drug delivery through the corneal layers can be attributed to 
multivalent interactions with glycocalyx and ocular mucins. Pharmacokinetic studies of 
concentrations of topically instilled puerarin in the form of PAMAM-puerarin complexes 
were carried out using micro-dialysis and mass spectroscopy, which suggested that up to 
a 3.5- fold increase in drug concentration, could be achieved in groups treated with 
PAMAM dendrimer-drug complexes, compared to the free drug [22]. Synthetic 
antiglaucomatic drugs, timolol and brimonidine are hydrophobic and have very limited 
solubility in aqueous ophthalmic solutions and dramatically influence their cellular 
uptake, corneal transport and bioavailability. Developed dendrimer hydrogel (DH) 
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consisting PAMAM (G3-NH2) dendrimers with PEG acrylate chains (cross linkers) 
conjugated to their surface and brimonidine or timolol maleate encapsulated into their 
hydrophobic cores forming a viscous formulation are aimed to increase the 
bioavailability of drugs after topical instillations [23]. 
2) Desirable biodistribution and drug targeting in ocular tissues: Biodistribution, 
bioavailability and targeting of drugs are the key parameters that are necessary for 
evaluating and achieving desired efficacy. Nanoparticles and dendrimers can be designed 
with various surface modifications, decorating with targeting ligands to target specific 
cells or to cross the retinal barriers [24]. Delivery of drugs to retinal layers is a difficult 
task as the retina itself is isolated from blood circulation and vitreous fluid similar to the 
brain by the inner and outer BRB to maintain its homeostasis and clear vision. 
Dendrimers and nanoparticles showed differential biodistribution based on their size, 
surface charge and targeting ligands. Based on targeting ligands for example, 
Rhodamine-conjugated liposomes, loaded with the vasoactive intestinal peptide (VIP-Rh-
Lip), injected intravetrially were bio distributed in inner retinal layers and up taken by 
Müller and resident macrophages at earlier time points (24hrs) and finally retained in 
retinal pigment epithelium (RPE) upto 4 months, thereby manifesting their prolonged 
bioavailability [25]. Based on size polystyrene nanoparticles (2 µm, 200 nm, and 50nm) 
showed differential uptake. Larger particles (200µm) were cleared out from the vitreous 
chamber and were seen accumulated in trabecular meshwork, whereas smaller particles 
(50nm) were found crossing the retinal layers and the intermediate particles (100nm) 
were found both in trabecular meshwork, retinal layers and entangled in vitreous 
networks [26]. Dendrimers showed differences in biodistribution based on their 
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composition, size and route of administration. PAMAM dendrimers injected intravetrially 
showed pathology dependent accumulation in RCS rat models. They were specifically 
localized and up-taken by activated resident microglial cells in inner nuclear layers, 
photoreceptor layers where the degeneration & neuroinflammation occurs in many retinal 
diseases such as macular degeneration, CNV, retinitis pigmentosa, diabetic retinopathy 
and etc. In diseased retina the dendrimers were retained for more than 1month after single 
intravitreal injection retinas whereas in normal retina they were completely cleared out 
within 24hrs [27]. When dendrimers injected via intravenous route were distributed in 
outer retina and RPE layers. Polylysine dendrimers complexes with anti-vascular 
endothelial growth factor (anti-VEGF) oligonucleotides (ODN-1) targeted the RPE layers 
and suppressed neovascularization in CNV rat model for 3 weeks [28]. The above studies 
give us knowledge for wide opportunities for designing different dendrimer and 
nanoparticle formulations for desired biodistribution and prolonged availability for 
different diseases. 
3) Enhanced efficacy at lower drug concentrations: Achieving enhanced efficacy at very 
low drug concentrations and decreasing the frequency of dosages is always desirable for 
avoiding side effects from drug, retinal & ocular toxicity and achieve patient compliance. 
Delivery a drug via nanoparticle is a challenge in offers researchers an opportunity 
window to develop novel formulations and ultimately helps in clinical translation. 
PAMAM dendrimer (G4-OH) conjugated to fluocinolone acetonide (drug-anti-
inflammatory) (D-FA) showed sustained in-vitro release for 3months and in-vivo was 
shown to provide sustained attenuation of neuro-inflammation, long-term 
neuroprotection, along with maintaining photoreceptor. The attenuation of neuro-
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inflammation is done by reverting the proinflammatory activated resident microglia to its 
resting state and such targeted drug delivery is very beneficial in many neurodegenerative 
and neovascular retinal diseases [27]. Cytomegalovirus (CMV) retinitis, uveitis or 
microbial endophthalmitis leading to structural damage in the retina, retinal detachment 
or inflammation, resulting in a permanent vision loss. PAMAM dendrimer formulations 
were also investigated for their ability to increase efficacy in the case of intraocular 
infections and endophthalmitis where antibacterial and antiviral agents are injected in to 
the eye at very strong doses frequently and such high drug doses cause retinal toxicity. 
PAMAM dendrimer loaded with ofloxacin and fluconazole showed 4 fold better 
efficacies in inhibiting retinal infections at 6 fold lower doses than commercial 
formulations [29]. Carboplatin is an anticancer drug commonly used for intra ocular 
tumors and retinoblastoma but causes toxicity to optic nerve and corneal lens scarring at 
therapeutic levels.  PAMAM dendrimers with carboxyl end groups (G3.5-COOH) for 
extended half-life and sustained delivery of carboplatin with lowered therapeutic toxicity 
[30]. 
The above studies prove that dendrimer formulations can be beneficial for various 
applications such as ocular infections, corneal neovasculartion, glaucoma, corneal surgeries and 
corneal transplantation. Table 1 provides a summary of different dendrimer formulation studied 
and their enhanced results for different ocular diseases. 
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1.5.  Ocular neuroinflammation and neovascularization- a target of dendrimer 
therapeutics: 
As a part of central nervous system (CNS) retina and choroid are constantly under 
surveillance for maintaining their proper health and function. Retina is innervated directly from 
the branches of the optic nerve that relays to the optic center in the cerebral cortex of the brain. 
The optic nerve enters the retina via the optic disc and radially distributes and synapses with the 
ganglionic cells forming the nerve fiber layer. There are three major types of glial cells found in 
retina: Müller cells, astrocytes and microglia. Microglia enters the retina from the circulation and 
has phagocytic activity. On other hand the vascular supply to retina and choroid is intense and 
14 
 
crucial. Choroid receives 80% of all ocular blood. The choroidal blood vessels are not regulated, 
leaky and often have fenestrations up to 20nm.  In contrast, retina has regulated blood supply 
with all the blood vessels having tight junctions [inner blood retinal barrier (BRB)]. The 
ophthalmic artery enters the retina along with the optic nerve and radially branches out to supply 
the entire retina forming a network of retinal capillaries where the blood flow is highly regulated.  
 
  Figure 4: A schematic representation of Activated microglial interactions with retinal cells and their pathological 
effects. 
 
Microglial cells are responsible for maintaining the tissue metabolism and health by 
eliminating the invading microbes, clear cellular debris and also the house keeping function such 
as angiogenesis during early development, releasing growth factors when required and also 
maintaining the tissue inflammatory response by producing anti-inflammatory cytokines for 
neuronal survival. On other hand these microglial cells in the case of pathology where the 
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molecular signals and tissue damage passes beyond a certain limit causes themselves activated to 
pro-inflammatory cells [31]. Retinal microglia has been implicated in number of retinal 
degenerative diseases and vascular diseases. Activated microglia cells exhibit pathological 
changes both morphologically and functionally.  
It is widely accepted that microglia contribute the process of neurodegeneration by 
releasing and maintaining various neurotoxic factors and inflammatory cascades [32]. They 
perform and maintain numerous cross-talks with other cells in the retina such as neurons, RPE, 
ganglionic cells and endothelial cells. They produce agents like fibroblast growth factor causing 
retinal scarring and fibrosis thereby paving a way for neuronal cell death. Microglial cells were 
reported to cause ganglionic cell atrophy in disease conditions such as diabetic retinopathy and 
glaucoma and manifested by ganglionic layer thinning [33]. Microglial cells when activated have 
dynamic cell movement within the retina and tends it to accumulate in the photoreceptor and 
RPE layer. They also induce photoreceptor dystrophies in conditions such as retinal ischemia and 
dry AMD [27].  
Potential role of microglia in retinal blood vessel neovascularization was also reported as 
many cross-talk and molecular mechanisms [34]. They interact with perivascular cells that 
maintain the permeability of the blood vessels causing endothelial dysfunction by oxidative 
stress pathway [31] Moreover they were found accumulated in the neovascular tufts in mice 
model of laser induced CNV. Activated microglial cells causes RPE and endothelial cells to 
produce VEGF thereby causing promotion of pathologic blood vessels. They also decrease the 
expression of VCAM-1 and increases the ICAM-1 expression in retinal endothelial cells thereby 
the blood vessels lose their vascular integrity. Increase in ICAM expression causes circulatory 
and choroidal macrophages to infiltrate in to the retina exacerbating the disease process [35]. A 
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schematic representation of effects of activated microglia and their cross-talk with various retinal 
cells is depicted in Figure 4. 
1.6.   Research Objective: 
Eye is a complex and delicate organ well supplied with neurons and rich vasculature. They 
are connected directly to the CNS and share many common properties. Ocular diseases are 
projecting a major health problem and the cost of treating the ocular diseases increases every 
year. Neuroinflammation and neovascular are the two major events that occur in many retinal 
diseases such as age related macular degeneration (AMD), diabetic retinopathy (DR), choroidal 
neovascularization (CNV), and etc. Neuroinflammation mediated by activated microglia plays a 
key role in many retinal degenerative diseases as aforementioned. Activated microglial cells 
display multifaceted changes in all aspects - phenotypically, morphologically and physiological 
causing damage to neurons and ganglionic cells. Additionally these proinflammatory microglial 
cells have intense cross-talk with RPE and endothelial cells causing disruption in retinal barriers 
and leading to infiltration of macrophages thereby making retina viable for disturbed hemostasis 
and function. Hence, therapeutic strategies that target neuroinflammation will be beneficial. 
 On other hand delivery of drugs to the eye is a challenge as in free form causes ocular 
toxicity at therapeutic levels. In many cases the drug molecules are cleared out and requires 
frequent multiple dosage causing side effects and patient incompliance. Systemic delivery of 
drugs is not effective in above cases and requires high dosages as only 2% of the injected dose 
reaches retina but such high dosage may cause systemic toxicity.  Dendrimer mediated drug 
delivery offers many advantages such as high drug pay load, sustained delivery and effective 
targeting. Dendrimers have been investigated and reported to target and selectively localize in 
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activated microglia in brain and retina upon systemic and intravitreal injections without any 
targeting ligands respectively. Hydroxyl terminated (G4-OH) PAMAM dendrimers upon 
systemic injection are cleared intact from circulation through kidney urine without causing any 
organ toxicity. Dendrimer – drug conjugates significantly improved therapeutic in animal models 
of neuroinflammation induced cerebral palsy and retinitis pigmentosa. Based on the  literature 
and preliminary studies from our lab, we are aiming to develop and evaluate PAMAM  
dendrimer based nanotherapeutics for targeting retinal neuroinflammation via systemic delivery 
and also investigate their enhanced therapeutic potential of the same both in-vitro and in-vivo. 
Four specific goals are persuaded 1) Development of G4-OH PAMAM dendrimer-drug 
conjugates for ocular drug delivery. 2) Development of G4-OH PAMAM dendrimer based Gene 
delivery formulation for ocular gene delivery. 3) Evaluating the ocular biodistribution of 
dendrimers injected intravenously in ischemia reperfusion (I/R) mice model and 4) Efficacy of 
dendrimer-drug conjugates in rat model of CNV. Harnessing the amicable properties of 
dendrimers having multiple functional groups multiple copies of drug or different kinds of 
molecules can be conjugated to same dendrimer (multifunctional dendrimer). By choosing 
appropriate linker (spacer) between the dendrimer and the drug molecule will result in stability 
of the drug, desired release profile, and high drug payload. Designing and developing the 
conjugates involves various linking chemistries, modification of surface groups and its proper 
characterization using various methods.  
 In this thesis four chapters are discussed. In Chapter 1 and overview of dendrimer and 
their role in ocular drug delivery is summarized. The synthesis, characterization and evaluation 
of in-vitro efficacy of dendrimer-triamcinolone acetonide (D-TA) conjugates for sustained 
treatment of ocular inflammation and neovascularization are described in Chapter 2. Designing 
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and developing a formulation for safe delivery of gene into hard to transfect human retinal 
pigment epithelial cells (RPE) is described in Chapter 3.  Chapter 4 describes the ocular 
biodistribution and microglial uptake of intravenously and intravitreally injected dendrimer in 
mice I/R model. Chapter 5 discusses evaluation of efficacy of the prepared conjugates in rat 
model of CNV.  
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CHAPTER 2 “SYNTHESIS, CHARACTERIZATION, AND IN-VITRO EFFICACY OF 
PAMAM DENDRIMER-TRIAMCINOLONE ACETONIDE CONJUGATES FOR   
OCULAR DRUG DELIVERY” 
2.1 Abstract 
Triamcinolone acetonide (TA) is an intermediate acting, potent steroid that has anti-
inflammatory and anti-angiogenic activity. It is typically and administered intravitreally for 
retinal inflammation and neovascularization.  Since large concentrations of TA are injected in to 
the eye due to its insolubility often causes vision blurring, retinal toxicity and damage and 
elevated IOP. In this study we explore PAMAM dendrimer-TA nanodevice (D-TA) as a potential 
option to overcome TA’s disadvantages. The conjugates have high drug payload (~21%) and 
were readily soluble in aqueous solutions. D-TA was significantly less toxic than compared to 
free TA in both microglial and retinal pigment epithelium (RPE) cells which were reported to be 
involved in pathogenesis of many retinal diseases. Interestingly, the conjugates showed 
significant suppression of cytokines and VEGF production in activated microglia and hypoxic 
RPE at ~100 fold lower concentration than compared to free TA. We also demonstrated that D-
TA enhanced intracellular transport of TA and also it’s enhances intra-nuclear localization via 
glucocorticoid (GR) receptors. 
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2.2. Introduction 
 Synthetic corticosteroids such as Triamcinolone acetonide (TA) have both anti-
inflammatory and anti-angiogenic activity and are thereby therefore a popular choice of viable 
therapeutic options for treating various inflammatory and neovascular ocular pathological 
conditions [36,37]. Triamcinolone acetonide (TA) on other hand is a FDA- approved gluco-
corticosteroid used intravitreally for diabetic macular edema [38], post-operative retinal surgery 
related inflammation, and other diseases with aforementioned conditions such as choroidal 
neovascularization (CNV) [39-41], age related macular degeneration (AMD) [42-47], diabetic 
retinopathy (DR) [45], scleritis and uveitis [46,47].  
 Several independent in-vitro and clinical investigative studies have been reported the 
multimodal therapeutic effects of TA [48]. For instance, TA exerts anti-inflammatory effect 
inhibiting microglial activation by suppressing the release of inflammatory cytokines and nitric 
oxide (NO) [49, 50]. TA reduces VEGF expression in RPE cultures that were subjected to 
oxidative stress, which is more similar to the state of pathologic in AMD and similar results were 
manifested with significant reduction neovascularization in many clinically relevant animal 
models [51-54]. Intracellular and vascular cell adhesion molecule (ICAM-1 and VCAM-1) and 
major histocompatibility complexes (MHC-I &II) are the critical components involved in 
leukocyte and monocyte infiltration, extravasation leading to blood retinal barrier (BRB) 
disruption and  vessel leakage respectively [55].  TA improves BRB health by enhancing the 
expression of adhesion molecules in endothelial cells [56], and significantly suppressing the 
blood vessel formation in choroidal endothelial cells [57].  
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 One advantage of possible explanation for the prolonged activity of intravitreal TA has 
prolonged duration of action possiblyis that it may form epi-retinal crystals in the vitreous due to 
its lack of solubility, acting as drug depot, due it its insolubility and hydrophobic nature making 
them to form crystals in vitreous and act as depot injection [58], though this characteristic has 
also been attributed to toxicity problems. When injected intravitreally, precipitation of TA in 
vitreous. This precipitation can cause visual obscurity with unequal distribution, and as time 
progress they tend to settle forming epi-retinal crystals causing mechanical damage and local 
toxicity to the retinal tissue [58, 59]. To address insolubility and sedimentation issues, TA 
formulations with benzyl alcohol or benzalkonium chlorides as vehicle preservatives were 
commercialized but resulted in vehicle- mediated toxicity and sterile-endophthalmitis [60, 61].  
Other side effects associated with TA are evaluation of intraocular pressure (IOP), 
cataractogenesis and photoreceptor cell death [62]. 
 PAMAM dendrimers are the class of branched polymeric nanocarriers that are being 
investigated for ocular drug and gene delivery [63, 64]. Their amicable properties such as small 
size, multivalency and water solubility allows high pay load for many biologically unstable drugs 
[65, 66].  Therefore, dendrimer-TA conjugates may be a viable formulation for targeted 
intracellular delivery of TA. Upon intravitreal administration, Dendrimer dendrimer fluocinolone 
acetonide (D-FA) conjugates upon intravitreal injection selectively co-localized in activated 
microglial cells and attenuated retinal inflammation for a period of 30 days at a 30- fold lower 
concentration than that of free drug [67]. Upon systemic administration, dendrimer N-acetyl 
cysteine conjugates (D-NAC) accumulates accumulated selectively only in the area of 
inflammation in the brain and dendrimer N-Acetyl cysteine conjugates (D-NAC) shown to 
attenuated neuroinflammation and improved the motor function in rabbit model of cerebral palsy 
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[68, 69]. We have reportedreported dendrimer-TA based gene delivery platform for safe delivery 
gene and enhanced transfection in human retinal pigment epithelial cells [70]. PAMAM  
dendrimer formulations increase the solubility of drugs such as pilocarpine, brimonidine and etc. 
in aqueous solutions by acting as cargos with drugs encapsulated in their cores, thereby 
enhancing their bioavailability and permeation in ocular tissues [71, 27].   
 In this chapter we investigate the ability of PAMAM dendrimers to deliver TA into 
human retinal pigment epithelial cells (hRPE). We synthesize, characterize and evaluate the 
efficacy of dendrimer-TA conjugates, relating to its anti-inflammatory and anti-VEGF activity.  
With all the preliminary data described above in the consideration, in this article we describe the 
synthesis and characterization, cytotoxicity and in vitro efficacy of generation 4 hydroxyl 
PAMAM dendrimer-TA conjugate (D-TA) with high loading (~21%).  The conjugates 
demonstrate superior solubility in aqueous solutions that free drug, sustained release, 
significantly enhanced anti-inflammatory and anti-VEGF activity with very low toxicity. We 
have show that D-TA conjuagtes also demonstrated the D-TA conjugates have result enhancedin 
enhanced cellular uptake, and with no compromise binding to glucocorticoid receptors and 
nuclear translocation in human retinal pigment epithelial cells. 
2.3. Material and methods 
2.3.1 Chemicals and reagents. 
Hydroxyl- and amine- functionalized ethylenediamine core generation four PAMAM 
dendrimers (G4-OH; diagnostic grade; 64 end-groups) were purchased from Dendritech Inc. 
(Midland, MI, USA). Triamcinolone acetonide (TA), glutaric anhydride, piperidine, N,N’-
diisopropylethylamine (DIEA), trifluoroacetic acid (TFA), anhydrous dimethylformamide 
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(DMF), dimethylacetamide (DMA) and 6-(Fmoc-amino) caproic acid  were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). (Benzotriazol-1-yloxy)tripyrrolidino-phosphonium 
hexafluorophosphate (PyBOP) was purchased from Bachem Americas Inc. (Torrance, CA, 
USA). Cy5-mono-NHS ester was purchased from Amersham Biosciences-GE Healthcare 
(Pittsburgh, PA, USA). ACS grade DMF, dichloromethane (DCM), diethylether, hexane, ethyl 
acetate, HPLC grade water, acetonitrile, and methanol were obtained from Fisher Scientific and 
used as received for dialysis, purification and column chromatography. Dialysis membrane (MW 
cut-off 1000 Da) was obtained from Spectrum Laboratories Inc. (Rancho Dominguez, CA, 
USA). 
The reactions were carried out under nitrogen. Thin-layer chromatography (TLC) was 
performed on silica gel GF254 plates (Whatman, Piscataway, NJ), and the spots were visualized 
with UV light. Proton NMR spectra of the final conjugates as well as intermediates were 
recorded on a Bruker (500 MHz) spectrometer using commercially available DMSO-d6 solvent. 
Proton chemical shifts were reported in ppm (δ) and tetramethylsilane (TMS) used as internal 
standard. All data were processed using ACD/NMR processor software (Academic Edition). 
2.3.2. Synthesis of Triamcinolone acetonide-21-glutarate (TA-linker, 1)  
TA (300 mg, 0.69 mmol) was dissolved in 10 mL of DMF/DMA mixture (8:2) in a 50 
mL round bottom flask under nitrogen atmosphere. Glutaric anhydride (158 mg, 1.38 mmol) 
dissolved in 5 mL of DMF/DMA mixture (8:2), and 0.35 mL of TEA were added to it and the 
reaction mixture was stirred for 48 h to complete the reaction. The completion of the reaction 
was monitored by thin layer chromatography using ethyl acetate/methanol (95:5) as mobile 
phase. The solvent was evaporated under reduced pressure and the crude product was purified 
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with column chromatography by passing through silica gel using ethyl acetate:methanol (99:1) as 
eluent to get TA-21-glutarate (348 mg, >90% yield). The obtained purified product was 
characterized by using 1H NMR spectroscopy. 1H NMR (DMSO-d6): δ 0.81 (s, 3H, -CH3), 1.13 
(s, 3H, -CH3), 1.33 (s, 3H, -CH3), 1.47-1.56 (m, 5H, -CH2 and -CH3), 1.68-2.04 (m, -CH2 of 
linker and -CH proton of TA), 2.20-2.34 (m, -CH2 of linker and -CH protons of TA), 2.43-2.47 
(t, -CH2 protons of linker), 2.57-2.64 (m, 1H, -CH), 3.57 (s, 1H, -CH), 4.18 (brs, 1H, -CH), 4.72-
4.85 (m, 2H, -CH), 5.11-5.15 (d, 1H, -CH), 5.47-5.48 (d, 1H, -CH), 6.00 (s, 1H, aromatic 
proton), 6.21-6.24 (dd, 1H, aromatic proton), 7.26-7.29 (d, 1H, aromatic proton), 12.10 (bs, 1H, 
COOH proton). 
2.3.3. Synthesis of Dendrimer-Triamcinolone acetonide conjugates (D-TA, 2). 
 TA-21-glutarate (TA-Linker,139.8 mg, 0.255 mmol) was dissolved in anhydrous DMF (5 
mL) in a 50 mL round bottomed flask under nitrogen, to which PyBOP (266.2 mg, 0.516 mmol) 
dissolved in DMF (5 mL) and DIEA (200 µL) was added, and the reaction mixture was allowed 
to stir for 1 hour in an ice bath. PAMAM G4-OH (238.8 mg, 0.017 mmol) dissolved in 
anhydrous DMF (10 mL) was added drop wise to the reaction mixture above, and stirred for 48 
hours under nitrogen.  The mixture of solvents was evaporated at 25°C under vacuum. The crude 
product was redissolved in DMF (20 mL) and subjected to dialysis in DMF (membrane MW 
cutoff = 1 kDa) for 24 hours, where the solvent was changed at least 4 times. The obtained 
solution was evaporated under reduced pressure at room temperature, followed by  high vacuum 
overnight, to produce an off-white semi-solid dendrimer-triamcinolone conjugate (D-TA, 470.9 
mg). The resultant semi solid product was dissolved in ice cold DI water and dialyzed against DI 
water (membrane MWCO = 1 kDa) at 4ºC for 5 hours by changing the water every hour to 
remove traces of DMF. The resultant water layer was lyophilized to get fluffy white powder of 
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D-TA (402.3 mg) (Figure S1-B). The D-TA conjugates were characterized by 1H NMR for drug 
loading and reverse-phase HPLC for purity. 1H NMR (DMSO-d6) δ 0.82 (s, -CH3 protons of 
TA), 1.14 (s, -CH3 protons of TA), 1.34 (s, -CH3 protons of TA), 1.49 (s, -CH3 protons of TA), 
1.53-2.05 (m, -CH protons of TA, -CH2 protons of linker), 2.20 (brs, -CH2 protons of G4-OH), 
2.31-2.48 (m, -CH protons of TA, -CH2 protons of linker, -CH2 protons of G4-OH), 2.64 (bs, -
CH2 protons of G4-OH), 3.09-3.11 (t, -CH2 protons of G4-OH), 3.28 (m, -CH2 protons of G4-
OH), 3.38-3.40 (t, -CH2 protons of G4-OH), 3.58 (s, -CH protons of TA), 4.00-4.02 (m, 
CH2OC=O protons, G4-OH), 4.20 (brs, -CH protons of TA), 4.73-6.01 (singlets and doublets, -
CH protons of TA, OH protons of G4-OH), 6.22-7.31 (two doublets, aromatic protons of TA), 
7.79-8.07 (m, amide protons of G4-OH). 
2.3.4. Synthesis of bifunctional dendrimer (D-OH-NHFmoc, 3) 
Fmoc-caproic acid (62.3 mg, 0.176 mmol) was dissolved in DMF (5 mL) in a 50 mL 
round bottom flask under nitrogen environment. PyBOP (152.7 mg, 0.2935 mmol) dissolved in 
DMF (5 mL) and DIEA (150 µL) were added, and the reaction mixture was allowed to stir for 1 
h in an ice bath. Finally, PAMAM G4-OH (164.4 mg, 0.022 mmol) dissolved in anhydrous DMF 
(10 mL) was added to the reaction mixture and stirred for 48 h. The mixture of solvents was 
evaporated at 25°C under vacuum. The crude product was redissolved in DMF (20 mL) and 
subjected to dialysis in DMF (membrane MW cutoff = 1 kDa) for 26 h by changing the solvent 
at least 3 times. The obtained solution was evaporated under reduced pressure at room 
temperature, and the final product was subjected to high vacuum overnight, to produce an off-
white semi-solid Fmoc-functionalized dendrimer (D-OH-NHFmoc, 3, 190 mg). 1H NMR 
(DMSO-d6) δ 1.24-1.51 (m, CH2 protons of linker), 2.26 (bs, CH2 protons of G4-OH), 2.38-
2.47 (m, CH2 protons of G4-OH, and CH2 protons of linker), 2.73 (CH2 protons of G4-OH), 
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3.12-3.13 (CH2 protons of G4-OH), 3.28 (CH2 protons of linker), 3.39-3.42 (CH2 protons of 
G4-OH) 4.00 (bs, CH2OC=O protons of G4-OH), 4.20 (bs, CH proton of Fmoc group), 4.29 (bs, 
OCH2 protons of Fmoc group), 4.73 (bs, OH protons of G4-OH), 7.26-7.68 (m, aromatic protons 
of Fmoc), 7.88-8.07 (m, aromatic protons of Fmoc, and internal amide protons of G4-OH). 
2.3.5. Synthesis of Fmoc-functionalized dendrimer-Triamcinolone acetonide conjugate (4) 
 TA-linker (107.6 mg, 0.196 mmol) was dissolved in 5 mL of anhydrous DMF under 
nitrogen atmosphere in a 50 mL round bottomed flask, and PyBOP (255.5 mg, 0.49 mmol) and 
DIEA (220 µL) were added to it. The reaction mixture was stirred at 0°C in an ice bath for 30 
min followed by the addition of D-OH-NHFmoc (227.2 mg, 0.013 mmol) dissolved in DMF (10 
mL), and the reaction was allowed to stir for 48 h under nitrogen condition. The reaction mixture 
was evaporated under reduced pressure and dialyzed in DMF for 24 h, while  the solvent was 
replaced every 6 h (dialysis membrane cutoff = 1 kDa) to remove the unreacted starting materials 
and byproducts. The resultant DMF was evaporated, and the conjugate was dissolved in water 
and re-dialyzed against water for 6 h and lyophilized to get Fmoc-functionalized D-TA conjugate 
(4) as an off-white color solid product (280 mg). The conjugate was characterized by 1H NMR, 
and the drug loading was assessed using the proton integration method. 
2.3.6. Synthesis of bifunctional dendrimer-triamcinolone acetonide conjugates (NH2-D-TA, 
5) 
The Fmoc-functionalized dendrimer intermediate (4, 180 mg) was dissolved in anhydrous 
DMF (10 mL) and piperidine/DMF (2:8; 10 mL) was added to it under nitrogen. The reaction 
mixture was stirred for 30 min. and solvent was evaporated under vacuum at room temperature. 
The resultant crude product was subjected to dialysis in DMF (membrane MWCO = 1 kDa) for 
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24 h. The solvent was evaporated and the conjugate was re-dialyzed against water for 3-4 h and 
lyophilized to get NH2-D-TA, 5 (120 mg) as off-white solid product with free amine groups. 1H 
NMR (DMSO-d6) δ 0.83 (s, -CH3 protons of TA), 1.15 (s, -CH3 protons of TA), 1.24-1.53 (m, -
CH3 protons of TA, and -CH2 protons of linker), 1.71-2.06 (m, -CH protons of TA), 2.21-2.65 
(m, -CH2 protons of G4-OH, -CH protons of TA), 3.10-3.12 (t, -CH2 protons of G4-OH), 3.28 
(bs, -CH2 protons of G4-OH), 3.39-3.41 (t, -CH2 protons of G4-OH), 4.01 (d, CH2OC=O 
protons of G4-OH), 4.20-7.31 (singlet and doublet, -CH and aromatic protons of TA), 7.80-8.07 
(m, amide protons of G4-OH). 
2.2.7. Synthesis of Cy5-labeled dendrimer-triamcinolone acetonide conjugates (Cy5-D-TA, 
6). 
The NH2-D-TA (5), (25 mg, 0.0013 mmol) was dissolved in 1 mL of borate buffer (pH 
9.0) at room temperature. The reaction mixture was cooled to 0°C, and Cy5 mono NHS ester 
(2.18 mg, 0.0027 mmol) dissolved in 1 ml of DMF was added. N-Hydroxysuccinimide (1.58 mg, 
0.013 mmol) dissolved in 500 µL of DMF was added to reaction.  The reaction mixture was 
stirred overnight at room temperature. The crude product was dissolved in water and subjected to 
dialysis against pure DI water (membrane MWCO = 1 kDa) for 12 hours with successive change 
of water in every 2 hours at 4ºC. The resultant water layer was lyophilized to get Cy5-D-TA, 5 
(12.8 mg). The Cy5-D-TA was characterized by reverse-phase HPLC for purity, and 
fluorescence spectroscopy. 1H NMR (DMSO-d6) δ 0.82 (s, -CH3 protons of TA), 1.14 (s, -CH3 
protons of TA), 1.23-1.26 (m, -CH2 protons of linker), 1.34 (s, -CH3 protons of TA), 1.48-1.52 
(s, -CH3 protons of TA, -CH2 protons of linker), 1.69-2.04 (m, -CH protons of TA, -CH2 
protons of linker), 2.20 (bs, -CH2 protons of G4-OH), 2.39-2.47 (m, -CH protons of TA, -CH2 
protons of linker and -CH2 protons of G4-OH), 2.64 (bs, -CH2 protons of G4-OH), 3.09-3.11 (t, 
28 
 
-CH2 protons of G4-OH), 3.38-3.40 (t, -CH2 protons of G4-OH), 4.00-4.01 (d, CH2OC=O 
protons of G4-OH), 4.20-7.33 (singlet and doublet, -CH and aromatic protons of TA and Cy5), 
7.65 (s, aromatic protons of Cy5), 7.79-8.05 (m, amide protons of G4-OH), 8.38 (m, aromatic 
protons of Cy5). 
2.4. Characterization of the conjugates 
2.4.1 High performance liquid Chromatography (HPLC). 
The purity of the dendrimer conjugates was analyzed by HPLC (Waters Corporation, 
Milford, MA) equipped with a 1525 binary pump, a 2998 photodiode array (PDA) detector, a 
2475 multi-wavelength fluorescence detector, and a 717 auto sampler (kept at 4°C) interfaced 
with Empower software. The HPLC chromatograms were monitored at 205 (G4-OH) and 238 
nm (TA conjugated dendrimers) using PDA detector. For Cy5-labelled conjugates, fluorescence 
detector was used for the detection (excitation: 645 nm and emission: 662 nm). The 
water/acetonitrile (0.1% w/w TFA) was freshly prepared, filtered, degassed, and used as mobile 
phase. A TSK gel ODS-80 Ts (250 X 4.6 mm, i.d., 5 µm) with TSK gel guard column were used 
for the study (Tosoh Bioscience LLC, Japan). A gradient flow was used with initial condition of 
90:10 (H2O/ACN) was maintained until 20 min and gradually changing the ratios to 10:90 
(H2O/ACN) at 40 min and returning to initial conditions 90:10 (H2O/ACN) in 60 min with flow 
rate of 1 mL/min for all conjugates. 
2.4.2 Dynamic light scattering (DLS) and Zeta potential (ζ). 
The particle size and ζ-potential of G4-OH, PEG and their respective conjugates were 
determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instrument 
Ltd. Worchester, U.K) equipped with a 50 mW He-Ne laser (633 nm). The conjugates (G4-OH, 
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D-TA and NH2-D-TA) were dissolved in deionized water (18.2 Ω) to make the solution with the 
final concentration of 0.1 mg/mL. The solution was filtered through a cellulose acetate 
membrane (0.45 micron, PALL Life Science) and DLS measurements were performed in 
triplicate, at 25°C with a scattering angle of 173°.  
2.4.3 Drug release study in simulated vitreous humor.  
 The release of TA from the D-TA conjugate was characterized in simulated vitreous 
humor [Hanks balanced salt solution with 0.03% sodium hyaluronate (Lifecore biomedical, MN, 
USA) and 0.1% Tween 80 (DakoCytomation, CA, USA)] as a stabilizer and surfactant to reduce 
released TA settling. A concentration of 3mg/mL was maintained in water bath at 37ºC equipped 
with shaker. At appropriate time points, 200µL of solution was withdrawn from the incubation 
mixture, frozen in liquid nitrogen and lyophilized. To this lyophilized powder, 400µL of 50:50 
(DCM:EtOAc) was added and sonicated for 10 min and centrifuged at 10,000 rpm for 5min at 
4ºC. The supernatant was collected and the solvent was evaporated by nitrogen flush and 
reconstituted with 200µL of 50:50 H2O:ACN and subjected to HPLC analysis following the 
method described in HPLC section. The percent of released TA from D-TA was quantified using 
the calibration graph. 
2.5 In-vitro characterization of the conjugates. 
2.5.1 Cell culture. 
Murine brain microglial cells (BV-2) passage 18 (P:18) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Life technologies, Grand Island, NY) supplemented with 5% 
heat in activated fetal bovine serum (Hi-FBS, Invitrogen Corp., Carlsbad, CA) and 1% 
antibiotics (penicillin/streptomycin) (Invitrogen Corp., Carlsbad, CA). Human retinal pigment 
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epithelial cells (ARPE-19) passage 21 (P: 21) were cultured in DMEM/F12(1:1) (Life 
technologies, Grand island, NY)  supplemented with 10% HI-FBS and 1% antibiotics. The above 
mentioned cell cultures were in a humidified incubator at 37 °C with 5% CO2. 
2.5.2 Cytotoxicity assay. 
 BV-2 and ARPE-19 cells were plated at a concentration of 1.0x104/well in a 96 well 
plate (Costar, Cambridge, MA)  and incubated at 37ºC for 24 hrs in their respective growth 
medium. After 24 hrs the cells were treated with medium containing different concentrations 
(0.1-200µg) of TA and D-TA at increasing concentrations for 24 hrs. The cells treated with fresh 
medium serves as control. Cell viability was assessed by using MTT cell proliferation assay kit 
(Molecular probes, Invitrogen, Oregon, USA). Absorbance was read at 540 nm using 
fluorescence microplate reader (BioTek Instruments, Winooski, Vermont, USA) and cell 
viability was determined as percent absorbance relative to untreated control cells. 
2.5.3 Anti-inflammatory assay in microglial cells. 
 Microglial (BV-2) cells were plated at a concentration of 1X106 cells per well in a 12 
well plate. After 24hrs the microglial cells were activated using Lipopolysaccharides (LPS) 
(Sigma, St Louis, MO) at a concentration of 100ng/mL for 3hrs. After 3hrs of pre-activation of 
microglial cells the activated microglial cells confirmed as they assume an amoeboid shape, the 
cells were treated with 1mL of medium with 100ng of LPS containing various concentrations of 
free TA (1-100µg) and D-TA containing equivalent concentration conjugated TA that of free TA 
treated for 12hrs. A stock solution of 10mg/mL of free TA was prepared by dissolving TA in 
absolute ethanol and subjected to serial dilution immediately to obtain desired concentration 
thereby avoid settling of TA particles in aqueous medium. Whereas D-TA being  water soluble 
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was dissolved in medium and serially diluted to obtain desired concentrations. After 12 hours the 
medium containing free TA and D-TA were removed and the cells were washed with warm 
medium and replenished with new medium containing LPS.  
 The cell culture medium was sampled at 24 hours and 48 hours, immediately centrifuged 
at 1500 rpm for 5 min at 4ºC and subjected for TNF-α cytokine levels using a mouse TNF-α 
ELISA kit (R&D systems, Minneapolis, MN, USA).  
2.5.4 Anti-VEGF activity in oxidative stress exposed retinal pigment epithelial cells. 
 Retinal pigment epithelial cells (ARPE-19) cells were plated at an initial concentration of 
1x106 cells per well in a 12 well plate. After 24hrs the medium was changed every day until day 
5 to form RPE monolayers. The monolayers were exposed to hypoxia in a low oxygen incubator 
in a humidified atmosphere for 8hrs and medium is rapidly changed to fresh medium and 
incubated normal culture conditions (reoxygenation)  for 2hrs. After reoxygenation the 
monolayers were exposed to various concentrations of free TA and D-TA containing equivalent 
concentrations of TA in conjugated form for 24 hours. The monolayers with no treatment serves 
as positive control and the monolayers which were not exposed to hypoxia serve a negative 
control. After 24hrs of treatment the treatment medium was removed and the monolayer was 
washed with warm medium twice to remove any TA or D-TA particles and replaced with fresh 
medium and incubated at 37ºC overnight (18 hours). The culture medium was collected in 2 mL 
vials and centrifuged at 1000 rpm for 5 min at 4ºC to remove debris, the supernatant was 
immediately assessed for VEGF levels were assessed using human VEGF ELISA kit (R&D 
systems, Minneapolis, MN, USA). Optical density at the end point was measured at 540nm with 
wavelength correction at 570nm using fluorescence microplate reader (BioTek Instruments, 
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Winooski, Vermont, USA). The VEGF levels were calculated using the calibration graph 
according to the manufacturer’s instructions. 
 The monolayers were subjected to trypsin treatment and the cell pellets were collected 
via centrifugation. Total RNA was purified with TRIzol reagent (Life Technologies, Grand 
Island, NY) following the manufacturer’s instruction. 3 µg of total RNA were reverse-
transcribed to cDNA using High-capacity cDNA Reverse Transcription System (Life 
Technologies) according to the manufacturer’s instructions. qRT-PCR was performed with 
fastSYBR Green Master Mix (Life Technologies) by a StepOnePlus Real-Time PCR System 
(Life Technologies). The sequence of primer used for human VEGF forward primer 5′-
CAGCGCAGCTACTGCCATCCAATCGAGA-3′, and reverse primer, 5′-
GCTTGTCACATCTGCAAGTACGTTCGTTTA-3′ was used for amplification. Human 
GAPDH forward 5’-AATCCCATCACCATCTTCCA-3’, reverse 5’-
TGGACTCCACGACGTACTCA-3’  was used to normalize the expression levels of target gene 
and calculated by the comparative cycle threshold Ct method (2-ΔΔCt). 
2.6 Cell uptake and intracellular localization of D-TA 
2.6.1 Flow cytometry. 
The cellular uptake of Cy5-D-TA was measured via flow cytometric analysis. Cells were 
seeded in 12-well plates at an initial concentration of 1.0 × 105 cells/well and left to attach 
overnight. Cells were incubated with Cy5-D-TA or D-Cy5 at 2 µg/ml; at different time points (1, 
3,6 and 12 hours) the media was removed and cells were washed with 1x PBS as well as Trystan 
blue prior to being incubated with 1 volume of 0.25% Trypsin with EDTA for 5 min at 37°C. 
Two volumes of DMEM medium with 10% FBS were added to neutralize trypsin. The cellular 
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uptake of D-TA was measured using the Accuri C6 flow cytometer (BD Biosciences, San Jose, 
CA) with an FL4 band-pass filter with emission detection wavelength of 675/25 nm. Data were 
analyzed using the BD Accuri C6 software. The thresholds were set using untreated samples. 
2.6.2 Confocal microscopy. 
 ARPE-19 cells were seeded at a concentration of 1x105 in a glass 35 mm glass bottom 
culture dish (MatTek Corporation, Ashland, MA). The cells were incubated with Cy5-D-TA or 
D-Cy5 at 2 µg/mL and at different time points (1 h, 3 h, 6 h and 12 h) the media was removed 
and cells were washed with 1x PBS twice and fixed with 4% PFA and blocked with normal goat 
serum (NGS) for 2hrs at 4ºC. The blocked cells were stained for glucocorticoid receptors (GR) 
using anti-GR antibody (abcam) (1:200) overnight at 4ºC and then goat α rabbit Cy3 conjugated 
secondary antibody (life techonologies) (1:100) for 4 hours. The cells were washed and stained 
with DAPI (1:1000) for 10 min and imaged using confocal Zeiss LSM 710 microscope. 
2.7. Results and discussions 
2.7.1. Preparation of Triamcinolone acetonide-21-glutarate (TA-linker, 1) 
TA was functionalized with a carboxylic acid terminal group using glutaric acid as linker 
since an acid group is required to conjugate with the dendrimer according to a previously 
published procedure. In brief, TA was reacted with glutaric anhydride dissolved in DMA/DMF 
mixture in presence of triethylamine (TEA) as base to get the TA-linker (Figure 5). The TA-
linker was characterized by 1H NMR. TA has two reactive hydroxyl groups and the most reactive 
21-position hydroxyl group has reacted with glutaric acid via ester bond. Apart from the protons 
signal from TA, an additional multiplet at 1.79 (CH2 protons of linker), and two triplets at 2.32 
and 2.47 (CH2 protons of linker) confirmed the formation of the TA-linker.  A characteristic 
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peak at 12.12 ppm belonging to carboxylic acid confirmed that TA-linker has one acid group 
(Figure 6). 
 
Figure 5: Synthesis of Triamcinolone acetonide linker 
 
 
Figure 6: 1H NMR spectrum of triamcinolone acetonide-21-glutarate (TA-linker) in DMSO-d6. 
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2.7.2. Preparation of dendrimer-TA conjugate (D-TA, 2)  
The ester-linked dendrimer-triamcinolone acetonide (D-TA, 2) was prepared by a two-
step process as shown in Figure 7, and characterized by 1H NMR and HPLC. TA was 
functionalized with a carboxylic acid terminal group using glutaric acid as spacer. In brief, TA 
was reacted with glutaric anhydride dissolved in DMA/DMF mixture in presence of a base to get 
the TA-linker (1). The most reactive hydroxyl group at 21-position was reacted with anhydride 
to get an ester linkage. The structure of TA-linker was established by 1H NMR and the purity 
was determined by HPLC. In 1H NMR, characteristic peaks at 1.79, 2.32 and 2.47 ppm for CH2 
protons of the linker, and a peak at 12.12 ppm corresponding to carboxylic acid confirmed the 
formation of the TA-linker. The TA-linker was further conjugated with PAMAM dendrimer 
(G4-OH) using PyBOP as coupling reagent to get therapeutic conjugate, D-TA (2). In 1H NMR 
spectrum, four peaks in between 0.82-1.49 ppm represent methyl protons of the TA. 
Additionally, as shown in Figure 8A, apart from dendrimer and TA peaks in between 2.0-8.1 
ppm, a characteristic peak at 4.01 ppm was observed which corresponds to methylene protons of 
the dendrimer reacted with TA. Using NMR proton integration technique, we estimated that 
approximately 10 molecules of TA were conjugated to one dendrimer molecule (~21%). The 
conjugate is readily soluble in DI water, PBS buffer and saline, in contrast to free TA which has 
poor water solubility (Figure 16). The maximum solubility of free TA reported to be 21 µg/mL 
in PBS [38], whereas achieved-TA is soluble up to 4 mg/mL (on a TA basis), and corresponds to 
a 200-fold enhancement in solubility. 
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Figure 6: Preparation of the dendrimer conjugates. Preparation of the dendrimer-triamcinolone acetonide 
conjugate (D-TA, 2); and Cy5-labeled dendrimer-TA conjugate (Cy5-D-TA, 6). 
 
The purity of the conjugate and the TA-linker were determined using reverse phase 
HPLC. The hydrophobic free TA eluted at 37.1 min, whereas the TA-linker eluted at 39.0 min 
(with no trace at 37.1 min) At similar HPLC conditions, a broad peak at 36.0 min was observed 
for D-TA conjugate (monitored at 238 nm) which is different from that for the starting dendrimer 
(retention time 15 min). The conjugate is largely pure since we did not observe any 
‘characteristic’ peaks related to free TA and TA-linker. The broad peak of D-TA conjugate can 
be attributed to the high loading of TA (~10 molecules per dendrimer) resulting in some non-
polar character (Figure 9A). 
37 
 
 
Figure 7: Proton NMR spectra of dendrimer-triamcinolone acetonide conjugate (D-TA, 2) and Cy5-labelled 
dendrimer-TA conjugates (Cy5-D-TA, 6) in DMSO-d6. 
 
2.7.3. Preparation of Cy5 labelled dendrimer-triamcinolone acetonide conjugate (Cy5-D-
TA, 6)  
The Cy5-D-TA conjugate was prepared using a four-step process following a modified 
synthetic procedure published recently [64], (Figure 7). In the publication mentioned above, we 
have reported the preparation of Cy5-D-TA conjugate with more than 20 surface amine groups 
for the gene delivery study. For the present study, we designed Cy5-D-TA (6) with fewer amine 
groups on the surface of the conjugate, so that we could reacts approximately one molecule of 
Cy5.  In brief, Fmoc-caproic acid was reacted with the dendrimer using PyBOP as coupling 
agent, to get Fmoc-functionalized dendrimer (D-OH-NHFmoc, 3). Three multiplets (1.24-1.51 
ppm) for caproic acid CH2 protons, a singlet at 4.00 ppm for internal CH2 protons of G4-OH, 
and multiplets between 7.26-7.68 ppm for Fmoc aromatic protons in NMR spectra confirmed the 
formation of the intermediate (Figure 8). Using proton integration method, it was estimated that  
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Figure 8: Proton NMR spectrum of dendrimer- triamcinolone acetonide conjugate (NH2-D-TA, 5) in DMSO-d6 
 
7 linker molecules were reacted with the dendrimer. Further, the Fmoc-functionalized dendrimer 
(3) was reacted with TA-linker using PyBOP/DIEA to get Fmoc functionalized D-TA (4). In the 
1H NMR spectrum, peaks at 0.84-1.50 ppm represent methyl protons of TA, and peaks at 4.75-
6.25 ppm represent aromatic protons of TA along with dendrimer peaks confirmed the formation 
of the conjugate. The Fmoc groups were deprotected with piperidine in DMF to get dendrimer-
TA conjugate (NH2-D-TA, 5) and characterized by 1H NMR. The NH2-D-TA conjugate has few 
free amine groups which would react with Cy5. In the NMR spectrum, absence of aromatic 
Fmoc protons signal and presence of all signals related to TA confirmed the formation of the 
product. As per proton integration analysis, 6 molecules of TA and ~3 amine groups were 
present in NH2-D-TA conjugate. Finally, Cy5-mono-NHS ester was reacted with NH2-D-TA in 
DMSO/buffer (pH 8.9) mixture to get Cy5-labeled dendrimers-TA conjugate, Cy5-D-TA (6). 
The final conjugate was purified by dialysis and further by GPC fractionation and characterized 
by reverse-phase HPLC and NMR spectroscopy. In NMR spectrum, peaks corresponding to TA 
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and linker molecules were present as mentioned above along with Cy5 peaks (Figure 7B). In 
HPLC analysis free Cy5 eluted at 15.05 min whereas Cy5-D-TA eluted at 33.08 min as a broad 
peak (monitored at 645 nm excitation) confirming the formation of the conjugate free from 
unreacted dye (Figure 9B). Since one molecule of Cy5 dye was used in the reaction, we could 
not see intense peak in the NMR spectrum in aromatic region. 
 
Figure 9: HPLC chromatogram of A) D-TA and B) Cy5-D-TA conjugates. 
2.7.4. Particle size and zeta potential 
 Size and surface charge of the dendrimer conjugate influences its cellular entry, receptor 
binding or targeting to specific site of the tissue [57, 74].  We investigated the particle size and 
zeta potential G-OH (D), D-TA, and NH2-D-TA. The size of G4-OH was 4.4 ± 0.2 nm and zeta 
potential was slightly positive (4.5 ± 0.2 mV) due to their tertiary amines in its core. Upon 
conjugating ~10 molecules of TA to the dendrimer there was small increase in size (5.2 ± 0.3 
nm), but there was no change in its surface charge (4.2 ± 0.7 mV). In the case of NH2-D-TA 
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conjugate the size and zeta potential were 5.0 ± 0.5 nm and 5.9 ± 0.2 mV respectively. There is a 
small increase in the zeta potential due to the presence of 3-4 primary amine groups on the 
dendrimer surface after deprotection, which was further used for Cy5 conjugation. We couldn’t 
analyze the size and zeta potential of Cy5-D-TA due to the presence of Cy5 molecule and its 
interference with the laser used in the zetasizer.  
2.7.5. Release study:  
 In vitro release characteristics of D-TA conjugate were investigated in simulated vitreous 
humor as a physiologically relevant pH 7.0 mimicking the intravitreal injection of D-TA 
conjugates. A calibration curve for both TA and TA-linker was established over a concentration 
of 10 ng to 20 µg at 238 nm. We used HPLC method to quantify the release characteristics of the 
D-TA conjugate. The conjugate has two ester linkages that are susceptible to hydrolysis i) an 
ester linkage between the –OH group of the dendrimer surface and the -COOH group of the TA-
linker, and ii) another ester linkage between the hydroxyl group at 21- position of TA and the 
carboxyl group (-COOH) of one end of the glutaric acid linker. Our results suggest that the drug 
was released as free TA and TA-linker, confirmed by the two peaks that appeared in the HPLC 
chromatogram that coincide with the retention time of TA and TA-linker. Since there was an 
overlap of the peaks between the released drug forms and the conjugates, we adopted solvent 
precipitation method for extracting the released TA and TA-linker from the incubation mixture. 
The conjugates were insoluble in organic phase (DCM/ethyl acetate, 50:50) and precipitated out, 
while the organic phase containing the drug and drug linker was reconstituted in HPLC mobile 
phase and analyzed.  
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 D-TA conjugates released the drug more in the form of TA-linker than as TA. This 
phenomenon was also reported by Macky et al [66] where the ester bond between the TA and the 
linker was more stable for a period of 7 days.  The conjugates exhibited initial burst release of 
~18% of its payload within 24 hrs. From day 3 to day 20, there was a sustained release, with a 
further ~ 40% release, followed by a nearly zero order release over the period from day 20 to day 
45, resulting in ~95% of the payload released (Figure 10). The hydroxyl group in TA used in the 
conjugation is not required for any therapeutic activity or receptor binding [75, 76] and thus the 
dendrimer-TA may be able to maintain the same therapeutic activity as that of free TA. 
 
Figure 10: Drug release profile from D-TA conjugates in simulated vitreous humor 
2.8. in-vitro efficacy of D-TA conjugates in microglial and RPE cells.  
2.8.1. D-TA conjugates cytotoxicity assay in cells. 
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 The D-TA conjugates should be non-cytotoxic at the concentrations used in cell studies. 
We performed a cell viability assay to establish the range of concentrations where both free TA 
and D-TA are non-toxic, to establish the therapeutic window for efficacy studies in cells. 
Previous studies showed that 400 µg/mL TA was toxic to retinal cells [51], hence we treated the 
cells with preservative free TA within the concentration range from 0.1 to 200 µg/mL of TA and 
D-TA which contains equivalent concentrations of TA. We also tested the toxicity of free 
dendrimer based on the amount of dendrimer present in D-TA. Since we used ethanol to dissolve 
free TA and serially diluted with cell medium we also used the same amount of ethanol for D-
TA and controls. The ethanol treatment did not illicit any toxicity in both BV-2 and ARPE-19 
cells.  At 200 µg/mL, free TA showed significant decrease in % cell viability in BV-2 and 
ARPE-19 cells (58.3% ± 5.9% and 54.2% ± 6.8% respectively), but interestingly D-TA 
conjugates did not induce any cell death resulting (90.7% ± 8.5% and 91.6% ± 2.6%) 
respectively at this concentration (Figure 11A & 11B). We noticed that at the highest 
concentrations (200 µg/mL) free TA precipitated and formed crystals to some extent, and 
deposited over the cells (Figure 17), whereas D-TA is highly soluble and did not precipitate. 
Cytotoxicity of free TA can be attributed to the direct cellular contact with the epicellular 
crystals as noticed by Szurman et al in ARPE-19 cells [77]. Similar effect was also noticed at 
100 µg/mL of free TA but not with D-TA. At concentrations below 100 µg/mL, both free TA 
and D-TA did not show significant decrease in cell viability upon 24 hours of incubation. Free 
dendrimer did not show any cytotoxic effects in both cell types in any concentrations thereby 
negating the effect of delivery vehicle on cytotoxicity. 
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Figure 11:  Cytotoxicity of free TA and D-TA in A) BV-2 microglial cells and B) ARPE-19 cell. Cells were treated 
with varying concentrations of free TA and D-TA with equivalent of free TA. Cell viability was measured after 24 h 
of treatment and compared to non-treated controls. Data represents the mean ± SEM. 
 
2.8.2. Anti-inflammatory activity of D-TA conjugates in microglial cells. 
 For investigating the anti-inflammatory effect of D-TA conjugates, we used LPS induced 
pro-inflammatory murine BV-2 microglial cells, which play a critical role in mediatingretinal 
inflammation. LPS activates protein kinases in microglial cells through  toll-like receptors (TLR) 
pathway thereby stimulating the release of immune regulated proinflammatory cytokines such as 
TNF-α, IL-1β, IL-6 and etc. [78,79] . We used TNF-α suppression to evaluate the anti-
inflammatory properties of TA and D-TA. Upon LPS pretreatment, there was a significant 
increase (~15 fold) in TNF-α level at 24 hrs. We tested varying concentrations of LPS and 
verified that 100 µg/mL treatments did not induce any cell death at least until 72 hours after 
incubation (data not shown). Cells were treated with free-TA or D-TA for a 12 hour period, in 
the presence of LPS. The supernatant was replaced after 12 hours, with just LPS, but no D-TA 
and free TA. Therefore, these studies reflect the efficacy of free TA and D-TA treatment and 
their uptake by the cells over a limited time of 12 hours, studied at 24, 48 and 72 hours, in the 
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continuous presence of LPS over 72 hours. Free TA inhibited TNF-α production in a dose 
dependent manner, with a maximum reduction of ~28.2% at highest treatment dose of 100 
µg/mL at 24 hours post treatment, whereas at low concentrations (25, 10 and 1 µg/mL) did not 
show any significant inhibition in TNF-α levels. In comparison, D-TA conjugate treatment, 
containing equivalent TA concentration (e.g. 100 µg/mL), significantly reduced the TNF-α level 
(~66.4%) and exhibited superior anti-inflammatory properties compared that of free TA. At 24 
hours, the extent of TNF-α suppression achieved with 1 µg/mL of D-TA was better than that 
achieved with 100 µg/mL of free-TA. This may be attributable to the fact that the dendrimer 
increased the intracellular uptake of conjugated TA compared to free TA (Figure 12A).  
 
Figure 12: Anti-inflammatory activity of D-TA (TNF-α release ELISA): BV-2 cells (Passage 18) were activated 
using LPS (100ng/mL) and treated with indicated concentrations of free TA and D-TA containing equivalent 
amount that of free TA for 12 hrs and replaced with LPS medium. Five samples (medium supernatant) were used for 
each group at indicated time point post treatment, TNF-α was measured using mouse TNF-α ELISA Kit, A) 24 hrs 
D-TA treatment B) 48 hrs post D-TA treatment and C) 72 hrs post D-TA indicating TNF-α suppression data 
represents mean ± SEM *P<0.01 vs free TA and **P<0.01 vs group of LPS. 
 
At 48 hours post treatment, with continuous LPS exposure, free TA did not inhibit TNF-α 
production, even at the highest concentration (100 µg/mL). In contrast,  D-TA showed 
significant efficacy in suppressing TNF-α production in a dose dependent manner, resulting in 
~35% suppression at 1 µg/mL to ~65% at 100 µg/mL (Figure 12B). The dose-response upon D-
45 
 
TA treatment and the extent of suppression was similar to that seen at 24 hours, indicating that 
D-TA sustained the effect at least up to 48 hours. At 72 hours, free TA did not show any TNF-α 
suppression, whereas D-TA showed moderate suppression (~35% at 100 µg/mL) (Figure 12C). 
The sustained anti-inflammatory effect provided by D-TA at very low concentration promises 
improved therapeutic effect for inflammatory retinal diseases. 
2.8.3. Anti-VEGF activity of D-TA conjugates in retinal pigment epithelium (RPE). 
 To examine the effects of free TA and D-TA on VEGF production, we assessed the 
protein and mRNA expression by ARPE-19 cells after hypoxia. We used hypoxia-reoxygenation 
in order to induce oxidative stress, resulting in the upregulation and secretion of VEGF in RPE, 
which is one of the most important causes of retinal neovascular diseases [45]. Upon 6 hours of 
hypoxia exposure to ARPE-19 cell monolayers, we saw increased VEGF levels (2107.9 ± 230.7 
pg/mL). After exposure to hypoxia followed by 2 hours of re-oxygenation with fresh medium, 
the cells were treated with different concentrations of free TA and D-TA for 24 hours and then 
replaced with medium without TA or D-TA, and the VEGF ELISA was performed 24 hours after 
medium change. Both TA and D-TA treatments inhibited VEGF secretion in a dose dependent 
manner. Free TA treatment led to a maximum reduction of ~27% at 100 µg/mL concentration. 
D-TA treatment resulted in a significantly better inhibition of VEGF secretion (~60%) at 100 
µg/mL (Figure 13A). D-TA inhibition of VEGF at 1 µg/mL was significantly better than that 
achieved at a 100-fold higher level of free TA.  
For VEGF to be secreted from RPE, mRNA corresponding to VEGF has to be synthesized using 
transcription from DNA in the nucleus, from where they are released in to the cytoplasm 
translated to VEGF protein, and further secreted from cells. Corticosteroids induce their effect 
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via glucocorticoid receptor activation [37, 38] and suppressing the mRNA levels in the nucleus. 
To see if a reduced level of VEGF protein secreted by RPE cells after D-TA treatment is due to 
down regulation of mRNA synthesis in these cells, we performed RT-PCR analysis of mRNA 
isolated from the treated cells. The RT-PCR results were consistent with ELISA analysis 
showing VEGF protein suppression. The VEGF inhibition at the mRNA level, where 75% 
inhibition could be achieved with D-TA at 10-25 µg/mL, was significantly better than that for 
free TA (Figure 13B). At 100 µg/mL of D-TA, the inhibition was less than that achieved at 10 
or 25 µg/mL. This suggests that D-TA at too high a concentration may actually decrease 
efficacy, as seen in steroids in animal models of retinal diseases [80]. 
 
Figure 13: Anti-VEGF activity of D-TA in ARPE-19 cells: ARPE-19 (Passage 21) were subjected to hypoxia for 
6hrs and treated with D-TA and free TA (equivalent drug basis) at indicated concentrations for 24 hrs and replaced 
with culture medium. 24 hrs post treatment VEGF was analyzed using human VEGF ELISA kit and RT-PCR for 
mRNA expression A) VEGF secretion analysis in culture medium using ELISA (n=6) and B) VEGF mRNA 
expression levels relative to GAPDH using RT-PCR (n=3) data denotes mean ± SEM, *P<0.01 vs free TA and 
#P<0.01 vs group with no treatment. 
 
2.9. Cell entry and intracellular localization of D-TA conjugates. 
2.9.1. Enhanced cellular uptake of D-TA conjugates: 
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Flow cytometry analysis was performed to assess the effect of TA conjugation on the cellular 
uptake of D-TA.  Despite their similarity in size and surface properties, Cy5-D-TA demonstrated 
consistently higher uptake in ARPE cells in comparison to D-Cy5. Specifically, at 1, 3, 6 and 12 
hours the percentage of the cell population that had taken up Cy5-D-TA was 1.7-, 3.7-, 3.3- and 
2.2- fold higher than that of the cells that had taken up D-Cy5, respectively. The mean 
fluorescence intensity demonstrated a similar correlation. As expected, the cell uptake increased 
over time for both D-Cy5 and Cy5-D-TA treated cells (Figure 14).  
 
Figure 14: D-TA uptake by human ARPE-19 cells: Flow cytometric analysis of Cy5-D-TA and D-Cy5 cellular 
uptake by ARPE-19 cells: ARPE-19 cells were treated with Cy5-D-TA or D-Cy5 for 1 h, 3 h, 6 h and 8 h in order to 
assess the effect of TA-conjugation on dendrimer cell uptake. (A) The percentage of cell uptake at different time 
points demonstrated significantly higher uptake of Cy5-D-TA compared to D-Cy5 at 3h, 6h and 12 h of incubation. 
(B) The MFI of the cell population, indicating the absolute amount of dendrimer uptake, was higher following 
incubation with Cy5-D-TA compared to D-Cy5. Significance was only found at 12 h of incubation. *p<0.05  
 
Cellular uptake constitutes an important barrier to effective delivery of anti-inflammatory 
therapeutics. While delivery of TA with the use of various nanocarriers has been studied, this is 
the first study to demonstrate that TA conjugation on the surface of dendrimers enhances cellular 
uptake of the conjugate. These results are in accordance with our previous work demonstrating 
that dendrimer–based gene vector uptake and transfection can be significantly improved 
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following conjugation of TA [63]. This phenomenon may be attributed to the nuclear localization 
of D-TA gene vectors leading to decreased exocytosis [81]. 
2.9.2. D-TA conjugates translocate to the nucleus via glucocorticoid receptors 
 Corticosteroids exert their anti-inflammatory and anti-VEGF activity via glucocorticoid 
receptor (GR) pathway [38, 82]. Many studies have previously reported that TA binds to GR, 
resulting in the activation of GR, followed by translocation to the nucleus [76].  Since D-TA 
conjugates exhibited enhanced therapeutic activity than free TA, we used Cy5-D-TA to visualize 
the intracellular localization, GR binding, and the nuclear translocation of D-TA. We used 
confocal microscopy at different time points (3, 6, and 12 hours) to visualize the dynamics of GR 
receptors in RPE cells. We used anti-GR antibody (Cy3, green) and DAPI (blue) for staining the 
GR and nucleus respectively. In control (Figure 15A-D) and free TA cells (not shown), the GR 
receptors were seen distributed in the cytoplasm. In contrast, at 3 hours, in the Cy5-D-TA treated 
cells, the GR were seen concentrated around the nucleus (Figure 15E-H) (indicated by white 
arrows) and were further co-localized with the Cy5 signal (red, Figure 15, G) suggesting that D-
TA binds GR. Twelve hours post incubation, Cy5-D-TA and GR were co-localized in the 
nucleus and was confirmed by the yellow signal in merged panel (Figure 15 K-N). To depict the 
colocalization of Cy5-D-TA and GR, we digitally magnified a signal cell at 3 and 12 hours 
(Figure 15,I & O), indicating the GR concentrating around the nucleus and nuclear delivery of 
Cy5-D-TA respectively (white arrows).  
 The imaging results are in agreement with the flow cytometry results, indicating 
enhanced cellular uptake and nuclear localization of D-TA conjugates. The difference in the GR 
localization of the free TA and D-TA, and the fact that D-TA localizes with GR even at 3 hours  
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Figure 15: Cellular uptake and nuclear localization of D-TA conjugates in ARPE-19 cells using confocal 
imaging: Cy5 labelled D-TA (Cy5-D-TA, red) was used to probe the intracellular localization of D-TA and it’s 
binding to glucocorticoid receptor (GR, green) and nucleus (DAPI, blue). A-D control cells where GR receptors are 
in cytoplasm, E-H 3 hrs post Cy5-D-TA incubation white arrows indicating GR concentrated around the nucleus (I, 
digital zoom of single cell), K-N 12 hrs post D-TA-Cy5 incubation white arrows indicating nuclear localization of 
GR along with Cy5-D-TA (yellow merge) (O, Digital zoom of single cell white arrows indicating the nuclear 
localization). The cells were imaged at 63X magnification, bar -10 µm. 
 
[when we don’t expect appreciable drug release (Figure 10)] suggest that the dendrimer 
conjugate is binding to the receptor. Moreover, these results also suggest that conjugating TA to 
dendrimer using OH group at 21st position did not alter, or perhaps enhanced the binding of TA 
to the GR. The D-TA formulation appears to enhance the nuclear translocation of TA-GR 
complex. The increased intracellular uptake of D-TA, enabled in part by TA, is in good 
agreement with our previous reports that D-TA based dendrimer gene carriers showed enhanced 
transfection in RPE cells, compared to dendrimer gene carriers [63]. 
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Figure 16: Solubility of free TA and D-TA in PBS. Free TA was not soluble in any of the concentrations A) 0.5 
mg/mL, B) 1.0 mg/mL and C) 2.0 mg/mL and forms a turbid white and cloudy solution which later settles. Whereas 
D-TA conjugate D) were completely 
 
 
Figure 17: Light microscope images of BV-2 microglial cell culture treated with A) 100 µg/mL of free TA, and B) 
D-TA containing 100 µg/mL of TA. Free TA being insoluble in cell culture medium forms aggregate crystals and 
deposits over the cells which cause 
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2.10. Conclusions 
Neuroinflammation and neovascularization are the two important pathological events 
implicated in AMD, diabetic retinopathy, CNV and other retinal diseases [83-85]. Therapies that 
can target both these events will be highly beneficial. Corticosteroids, particularly TA, has both 
anti-inflammatory and anti-angiogenic activity and has been used clinically. Improved 
intracellular delivery can enhance efficacy of TA and reduce its side effects [38]. In this study 
we synthesized hydroxyl PAMAM dendrimer based D-TA conjugate with a high payload 
(~21%) that were a) highly water soluble and exhibited sustained release of TA ~2% per day for 
a period for ~45 days, b) less toxic and enhanced cellular uptake of TA and c) significantly more 
efficacious in its anti-inflammatory (activated microglial cells) and anti-VEGF activity (retinal 
pigment epithelial cells) than free TA.  
Microglial cells perform dynamic immune surveillance and are responsible in 
maintaining the normal retinal health [86]. However, under pathological conditions they become 
activated and contribute to BRB breakdown, cytokine production and stimulating RPE to 
produce VEGF leading to neovascularization [38, 84]. On the other hand, RPE cells are the 
major contributor for VEGF production [87], a factor involved in enhanced blood vessel 
permeability, abnormal neo-vessel formation resulting in leaky blood vessels [27]. The ability of 
D-TA to significantly suppress TNF-α in microglia for a period of 72 hrs, after a 12-hour 
treatment, suggests sustained anti-inflammatory action. In RPE cells, D-TA was fold more 
efficacious in inhibiting VEGF secretion, compared to a 100-fold higher concentration of free 
TA. In order for TA to exert its therapeutic effect, it needs to be transported into the cell, and 
further to the nucleus. From flow cytometry results it is evident that conjugating TA to the 
dendrimer enables more drug to be transported in to the cells. Interestingly, presence of TA on 
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the dendrimer seemed to increase dendrimer uptake. TA exerts its biological activity via 
glucocorticoid receptor (GR) pathway [88, 89]. In-vitro cell experiments, flow cytometry and 
qualitative results from con-focal microscopy suggest that D-TA enters nucleus along with GR to 
express its activity. Glucocorticoids down regulate VEGF by blocking up-stream of its 
transcription in the nucleus [38, 43, 90] which is evident from confocal images and RT-PCR 
studies where D-TA treatment showed low levels of VEGF mRNA. 
  Increased efficacy and decreased toxicity achieved with dendrimer conjugation of TA 
may be beneficial. TA is typically injected in relatively large doses (4 mg in human eyes) l 
resulting in various side-effects such as elevated IOP, retinal toxicity and blurred vision [91].  In 
this study we have demonstrated that both anti-inflammatory and anti-VEGF properties of TA 
can be enhanced by conjugating them to dendrimers resulting in efficacy at much lower 
concentrations (~100 fold) than that of free drug. Therefore, dendrimer-TA conjugates may be a 
viable formulation for targeted intracellular delivery of TA.  Further evaluation of the D-TA 
conjugates in clinically relevant animal models can provide more insights in terms of sustained 
efficacy, potentially offering a potent option for fighting against numerous retinal diseases such 
as AMD, CNV, diabetic retinopathy and macular edema. 
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CHAPTER 3 “SYNTHESIS, CHARACTERIZATION AND IN-VITRO EVALUATION 
OF PAMAM DENDRIMER BASED GENE CARRIER FORMULATION FOR OCULAR 
GENE DELIVERY” 
3.1. Abstract 
 Ocular gene therapy holds promise for the treatment of numerous blinding disorders. 
Despite the significant progress in the field of viral and non-viral gene delivery to the eye, 
important obstacles remain in the way of achieving high-level transgene expression without 
adverse effects. The retinal pigment epithelium (RPE) is involved in the pathogenesis of retinal 
diseases and is a key target for many gene-based therapeutics. In this study, we addressed the 
inherent drawbacks of non-viral gene vectors and combined different approaches to design an 
efficient and safe dendrimer-based gene delivery platform for delivery to human RPE cells. We 
used hydroxyl-terminated polyamidoamine (PAMAM) dendrimers functionalized with different 
amounts of amine groups to achieve effective plasmid compaction. We further used 
triamcinolone acetonide (TA) as a nuclear localization enhancer for the dendrimer-gene 
complex, and achieved significant improvement in cell uptake and transfection of hard-to-
transfect human RPE cells. To improve serum stability, we further conjugated the dendrimer-TA 
with neutral polyethylene glycol (PEG). The resultant complexes showed improved stability 
while minimally affecting transgene delivery, thus improving the translational relevance of this 
platform. 
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3.2. Introduction. 
The eye, as an immune privileged and easily accessible organ, constitutes a favorable 
target for gene therapy [92] The well-defined genetic targets that can alter the natural history of 
ocular disorders render gene therapy a promising therapeutic approach for numerous blinding 
disease entities such as Best’s disease, Stargatdt’s disease and retinitis pigmentosa [93-96] 
Indeed, gene therapy for Leber Congenital Amaurosis has demonstrated promising and long 
lasting results in clinical trials [98-101] 
Significant advances in the field of ocular gene therapy have been achieved with the use 
of viruses such as adeno-associated virus [99-102] While relatively efficient, viral gene vectors 
are limited by technical difficulties in scale-up, high cost of production [103] and risk of 
mutagenesis [104]. Moreover, repeated administrations or prior exposures may cause 
neutralizing immune responses, despite the immune privileged environment of the eye [105-
107]. Also, the size cut-off for the expression cassette that can be packaged in viruses excludes 
the delivery of large transgenes that may be effective in monogenic ocular diseases [108-110]. 
Non-viral gene vectors constitute an attractive alternative that can overcome most of the 
aforementioned limitations [111] in achieving ocular transgene delivery [112, 113] However, 
important issues such as vector or base-polymer cytotoxicity, instability in physiological 
solutions as well as low level of cellular uptake, nuclear transfer and transgene expression limit 
the clinical applications of nano-carriers [114]. Various cationic polymer-based gene delivery 
systems, such as dendrimers, have demonstrated effective transgene expression in vitro and in 
vivo [111]. The protonable amines of these gene vectors contribute to endosome escape and 
allow relatively high levels of transfection [115].  However, the same amine groups that enhance 
transfection lead to cytotoxicity, entrapment in physiological mesh-like barriers [116, 117] and 
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tendency towards nanoparticle aggregation. For these reasons, a variety of novel approaches 
have been used to overcome the inherent limitations of cationic polymer based non-viral gene 
vectors [111, 118] 
Dendrimers are globular branched macromolecules with a high density of tailorable 
surface groups [119]. The highly precise synthesis process produces polymers with low 
polydispersity and allows high control over their physicochemical characteristics. Different 
dendrimer types have been used as non-viral gene delivery vectors, with relatively promising 
results [120, 121]. While amine terminated PAMAM dendrimers demonstrate high levels of 
transfection efficacy, they are limited by cytotoxicity due to their amine functionalized surface 
[111]. Hydroxyl-terminated PAMAM dendrimers demonstrate improved safety profile and have 
proven to be effective drug delivery vehicles [122]. However, their near neutral surface charge 
and lack of protonable amines impedes their use in nucleic acid compaction and transgene 
delivery [123]. 
Triamcinolone acetonide (TA) is an intermediate-acting, relatively potent corticosteroid 
administered intravitreally for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis 
and other ocular inflammatory conditions not responsive to systemic corticosteroids. Due to its 
neuroprotective and anti-angiogenic properties, TA has also previously been used as an adjuvant 
therapy for diabetic macular edema (DME), retinal vein occlusion, and some forms of age related 
macular degeneration [125-127] TA has also been suggested to improve gene vector 
accumulation in the nucleus by acting as a nuclear localization signal, dilating the nuclear pores 
up to 60 nm when bound to its receptor [128] Ma et al. have demonstrated that TA conjugation 
on polyethylenimine as well as PAMAM dendrimers can significantly improve transgene 
expression of cationic polymer based gene vectors [129-130]   
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In this chapter we designed small compact gene vectors based on hydroxyl-terminated 
PAMAM dendrimers functionalized with a minimal number of primary amine groups [131] to 
allow for efficient compaction while maintaining their favorable safety profile. We further 
utilized TA to offset the lack of protonable amines and achieve high levels of safe transgene 
expression. Additionally, we used a poly-ethylene glycol surface coating to enhance colloidal 
stability of the aforementioned gene vectors in physiological solutions. We determined the 
physicochemical characteristics of the dendrimer-based gene vectors and examined the effect of 
the various complexation strategies on cell uptake and transfection efficiency in hard to transfect, 
sensitive and clinically relevant human retinal pigment epithelial cells [132-134]. 
3.3. Materials and methods 
3.3.1 Materials and reagents. 
 Hydroxyl- and amine- functionalized ethylenediamine core generation four PAMAM 
dendrimers (G4-OH and G4-NH2; diagnostic grade; 64 end-groups) were purchased from 
Dendritech Inc. (Midland, MI, USA). TA, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC.HCl) glutaric anhydride, piperidine, N,N’-diisopropylethylamine (DIEA), 
trifluoroacetic acid (TFA), anhydrous dimethylformamide (DMF), dimethylacetamide (DMA), 
and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 4-
(Fmoc-amino)butyric acid (Fmoc-GABA-OH) and (benzotriazol-1-yloxy)tripyrrolidino-
phosphonium hexafluorophosphate (PyBOP) were purchased from Bachem Americas Inc. 
(Torrance, CA, USA). Cy5-mono-NHS ester was purchased from Amersham Biosciences-GE 
Healthcare (Pittsburgh, PA, USA). mPEG2000 NHS ester was purchased from Creative 
PEGWorks (Winston Salem, NC, USA). ACS grade DMF, DMSO, dichloromethane (DCM), 
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diethylether, hexane, ethyl acetate, HPLC grade water, acetonitrile, and methanol were obtained 
from Fisher Scientific and used as received. Dialysis membrane (MW cut-off 1000 Da) was 
obtained from Spectrum Laboratories Inc. (Rancho Dominguez, CA, USA). 
3.3.2. Preparation of FMOC functionalized bifunctional dendrimer (BiD-FMOC, 1) 
 Fmoc-GABA-OH (287 mg, 0.882 mmol) was dissolved in DMF (5 mL) in a 50 mL 
round bottom flask under nitrogen environment. PyBOP (574 mg, 1.1035 mmol) dissolved in 
DMF (5 mL) and DIEA (200 µL) were added, and the reaction mixture was allowed to stir for 1 
hour in an ice bath. Finally, PAMAM G4-OH (309 mg, 0.022 mmol) dissolved in anhydrous 
DMF (10 mL) was added to the reaction mixture and was stirred for 48 hours.  The mixture of 
solvents was evaporated at 25 °C under vacuum. The crude product was redissolved in DMF (20 
mL) and subjected to dialysis in DMF (membrane MW cutoff = 1 kDa) for 26 hours by changing 
the solvent at least 3 times. The obtained solution was evaporated under reduced pressure at 
room temperature, and the final product was subjected to high vacuum overnight, to produce an 
off-white semi-solid Fmoc-functionalized dendrimer conjugate (BiD-Fmoc, 1, 460 mg). 1H 
NMR (DMSO-d6) δ 1.63 (m, CH2 protons, linker), 2.27-3.39 (m, CH2 protons of G4-OH and 
COCH2 protons of linker), 3.99 (bs, CH2OC=O protons, G4-OH), 4.18 (bs, CH proton of Fmoc 
group), 4.28 (bs, OCH2 protons of Fmoc group), 4.71 (bs, OH protons of G4-OH), 7.30-7.38 (d, 
aromatic protons of Fmoc), 7.65 (s, aromatic protons of Fmoc), 7.86-8.13 (m, aromatic protons 
of Fmoc, carbamate protons, and internal amide protons of G4-OH). 
3.3.3. Synthesis of Fmoc-functionalized bifunctional-Triamcinolone acetonide (BiD-Fmoc-
TA, 2)  
58 
 
TA-21-glutarate (70.6 mg, 0.129 mmol) was dissolved in 10 mL of anhydrous DMF 
under nitrogen atmosphere, and PyBOP (100.5 mg, 0.193 mmol) and DIEA (0.35 mL) were 
added to it. The reaction mixture was stirred at 0°C for 30 min. followed by the addition of BiD-
Fmoc (200 mg, 0.0086 mmol) dissolved in 10 mL of DMF, and the reaction was allowed to go to 
completion (48 h) under nitrogen conditions. The reaction mixture was evaporated under reduced 
pressure and dialyzed in DMF for 24 h, while  the solvent was replaced every 6 h (Dialysis 
membrane cutoff 1000 Da) to remove the unreacted starting materials and byproducts. The 
resultant DMF was evaporated, and the conjugate was dissolved in water and re-dialyzed  against 
water for 6 h and lyophilized to get BiD-Fmoc-TA acetonide conjugate (BiD-Fmoc-TA,3) as an 
off-white color solid product (220 mg). The conjugate was characterized by 1H NMR, and the 
drug loading was assessed using the proton integration method. 1H NMR (DMSO-d6) δ 0.84 (s, -
CH3 protons of TA), 1.15 (s, -CH3 protons of TA), 1.36 (s, -CH3 protons of TA), 1.47-1.55 (m, 
-CH3 and -CH protons of TA), 1.64 (s, -CH2 protons of linker) 1.73-1.82 (-CH proton of TA), 
1.92 (m, -CH protons of TA), 2.27 (m, -CH2 protons of G4-OH), 2.67-3.40 (m, -CH protons of 
TA, -CH2 protons of linker and -CH2 protons of G4-OH), 4.00 (s, CH2OC=O protons, G4-OH), 
4.19 (brs, -CH protons of Fmoc group), 4.29 (bs, OCH2 protons of Fmoc group), 4.70-6.25 (m, -
OH protons of G4-OH, -CH and aromatic protons of TA), 7.29-8.05 (m, carbamate protons, 
aromatic protons of Fmoc, aromatic protons of TA and amide protons of G4-OH). 
3.3.4. Synthesis of bifunctional-Triamcinolone acetonide (BiD-TA, 4) 
BiD-Fmoc-TA dendrimer (220 mg) was dissolved in anhydrous DMF (10 mL) and 
piperidine/DMF (2:8; 10 mL) was added to it under nitrogen. The reaction mixture was stirred 
for 30 min. and solvent was evaporated under vacuum at room temperature. The resultant crude 
product was subjected to dialysis in DMF (membrane MWCO = 1 kDa) for 24 h. The solvent 
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was evaporated and the conjugate was re-dialyzed against water for 3-4 h and lyophilized to get 
BiD-TA, 4(145 mg) as off-white solid product. The BiD-TA has some free amine groups and TA 
molecules on the surface. 1H NMR (DMSO-d6) δ 0.83 (s, -CH3 protons of TA), 1.15 (s, -CH3 
protons of TA), 1.35 (s, -CH3 protons of TA), 1.50 (s, -CH3 protons of TA), 1.54-2.07 (m, -CH 
protons of TA, -CH2 protons of linker), 2.21 (bs, -CH2 protons of G4-OH), 2.29-2.48 (m, -CH 
protons of TA, -CH2 protons of linker and -CH2 protons of G4-OH), 2.65 (bs, -CH2 protons of 
G4-OH), 3.10-3.12 (t, -CH2 protons of G4-OH), 3.28-3.29 (d, -CH2 protons of G4-OH), 3.28-
3.41 (t, -CH2 protons of G4-OH), 4.01-4.02 (d, CH2OC=O protons, G4-OH), 4.20-7.31 (singlet 
and doublet, -CH and aromatic protons of TA), 7.82-8.07 (m, amide protons of G4-OH). 
3.3.5. Synthesis of bifunctional dendrimer (BiD, 5) 
The whole batch of above BiD-Fmoc dendrimer was dissolved in anhydrous DMF (10 
mL) and 10 mL of piperidine/DMF (2:8) was added to it under nitrogen. The reaction mixture 
was stirred for 1 hour and the mixture of solvents was evaporated under vacuum. The crude 
product was co-evaporated with 10 mL of DMF under high vacuum and subjected to dialysis 
against DMF (membrane MWCO = 1000 Da) for 24 h. The solvent was evaporated and the 
product was triturated with diethylether to take out traces of DMF. Finally, the semi-solid 
product was re-dialyzed with pure DI water for 2-3 hours and subjected to freeze dryer to get 
bifunctional dendrimer (BiD, 280 mg). 1H NMR (DMSO-d6) δ 1.24-1.53 (m, CH2 protons, 
linker), 2.21 (bs, CH2 protons of G4-OH), 2.29 (m, COCH2 protons of linker), 2.43 (bs, CH2 
protons, G4-OH), 2.65 (bs, CH2 protons, G4-OH), 3.09-3.12 (t, CH2 protons, G4-OH), 3.27-
3.28 (d, CH2NH protons, linker), 3.38-3.41 (t, CH2 protons, G4-OH), 3.99-4.01 (t, CH2OC=O 
protons, G4-OH), 7.84-8.11 (m, NHCO protons of G4-OH). 
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3.3.6. Synthesis of amine dendrimer-mPEG2000 conjugate (G4-NH2-PEG, 6)  
The G4-NH2 dendrimer (100 mg, 0.007 mmol) was dissolved in borate buffer (10 mL) 
and EDC●HCl (134.5 mg) was added to it at 0°C. After 10 min mPEG2000 NHS ester was 
added and stirred the reaction mixture for 2 h. Finally the reaction mixture was dialyzed against 
water for 48 h (membrane cutoff: 8 kDa) and lyophilized to get PEG-functionalized dendrimer 
(G4-NH2-PEG, 6). The final product was characterized by 1H NMR, (DMSO-d6) δ 2.15-2.65 (-
CH2 protons of G4-OH), 3.08-3.10 (-CH2 protons of G4-OH), 3.25 (-OCH3 protons of PEG), 
3.36-3.66 (-OCH2 protons of PEG), 8.02-8.24 (amide protons of G4-OH). 
3.4. Characterization of the conjugates 
3.4.1. Proton NMR Characterization 
Proton NMR spectra of the final conjugates as well as intermediates were recorded on a 
Bruker (500 MHz) spectrometer using commercially available DMSO-d6 solvents. Proton 
chemical shifts were reported in ppm (δ) and tetramethylsilane (TMS) used as internal standard. 
All data were processed using ACD/NMR processor software (Academic Edition).  
3.4.2 High performance liquid Chromatography (HPLC) 
The purity of the dendrimer conjugates was analyzed by HPLC (Waters Corporation, 
Milford, Massachusetts) equipped with a 1525 binary pump, a 2998 photodiode array (PDA) 
detector, a 2475 multi-wavelength fluorescence detector, and a 717 auto sampler (kept at 4°C) 
interfaced with Empower software. The HPLC chromatograms were monitored at 210 (G4-OH) 
and 240 nm (TA conjugated dendrimers) using PDA detector. Fluorescence detector was used 
for the detection of Cy5-conjugated dendrimer (excitation: 645 nm and emission: 662 nm). The 
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water/acetonitrile (0.1% w/w TFA) was freshly prepared, filtered, degassed, and used as mobile 
phase. Symmetry C18 reverse-phase column, TSK gel ODS-80 Ts (250 X 4.6 mm, i.d., 5 µm) 
and TSK gel guard column were used for the study (Tosoh Bioscience LLC, Japan). A gradient 
flow was used with initial condition of 100:0 (H2O/ACN), gradually increasing to 90:10 
(H2O/ACN) in 10 min to 50:50 (H2O/ACN) in 20 min and returning to 100:0 (H2O/ACN) in 50 
min with flow rate of 1 mL/min for all conjugates.  
3.4.3. Fluorescence spectroscopy 
Fluorescence spectra of the Cy5-conjugated dendrimer (BiD-TA-Cy5) were recorded in 
phosphate buffer (0.1M) using a Shimadzu RF-5301 spectrofluorometer with excitation at 645 
nm and emission at 662 nm. To measure the fluorescence quantum yield of BiD-TA-Cy5 the 
absorbance at a wavelength of 645 nm and integrated fluorescence intensity following excitation 
at 645 nm of Cy5-conjugated dendrimer (BiD-TA-Cy5) and free Cy5 solutions at various 
concentrations were measured using the Synergy Mx Monochromator-Based Multi-Mode 
Microplate reader (Biotek, Winooski, VT). The quantum yield was calculated using the 
previously described comparative method47.   
3.4.4 Measurement of size and zeta potential of the conjugates  
Dendrimer conjugates were dissolved at 1mg/mL in 10 mM NaCl at pH 7.0. The ζ-
potential was measured by laser Doppler anemometry using a Nanosizer ZS90 (Malvern 
Instruments, Southborough, MA). 
3.4.5 Buffering capacity of dendrimer conjugates 
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Dendrimer conjugates were dissolved at a concentration of 0.2 mg/mL in 5 mL of 
ultrapure DI water.  Ultrapure water and PEI were used as a control. The initial pH was adjusted 
to 12.0 using 1.0 M NaOH and the solutions were titrated at 5 µL steps of 0.1 M HCl. The pH 
was measured using a microprocessor-based pH meter (Hanna instruments, Woonsocket, RI). 
3.5. Formulation and characterization of gene vectors 
3.5.1. Gene vector complexation 
The pBAL was produced by Copernicus Therapeutics Inc. (Cleveland, OH) and pEGFP 
plasmid was purchased by Clontech Laboratories Inc. (Mountain View, CA). The plasmids were 
expanded and purified as previously described.26 Plasmid was fluorescently labeled with Cy5 or 
Cy3 using Mirus Label IT® Tracker™ Intracellular Nucleic Acid Localization Kit (Mirus Bio, 
Madison, WI). The gene vector complexation was achieved by the drop-wise addition (1mL/min) 
of 10 volumes of plasmid DNA at a concentration of 0.1 mg/ml to 1 volume of a swirling 
polymer solution. Different polymer solutions were prepared with one or more dendrimer 
conjugates at nitrogen to phosphate (N/P) ratio of 5 unless otherwise specified. For the 
formulation of gene vectors with varying amounts of TA, blends of BiD-TA and BiD with a 
varying percentage of amine groups contributed by the BiD-TA polymer (100%, 75%, 50%, 
25%, 10%, 5%) were used. For the formulation of PEGylated gene vectors, blends of BiD-TA 
and D-NH2-PEG with a varying percentage of amine groups contributed by D-NH2-PEG (75%, 
50%, 25%) were used. The plasmid-polymer solutions were incubated for 30 min at room 
temperature to allow the formation of gene vectors. PEI and PEG-poly-L-lysine (PEG-PLL) gene 
vectors were formulated as previously described26 and used as controls in the following 
experiments.   
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3.5.2. Gene vector characterization 
Zeta potential and particle size 
The ζ-potential of the dendrimer complexes was measured in 10 mM NaCl at pH 7.0 by 
laser Doppler anemometry using a Nanosizer ZS90 (Malvern Instruments, Southborough, MA). 
The hydrodynamic diameter and polydispersity of the gene vectors were measured in an 
ultrapure water solution by dynamic light scattering using a Nanosizer ZS90.  
Transmission electron microscopy (TEM) 
In order to confirm their shape and size, the dendrimer-based gene vectors were imaged 
using transmission electron microscopy at 60,000x magnification (TEM, Hitachi H7600, Japan). 
Stability was assessed over time in ultrapure water at 4oC as well as in PBS buffer in room 
temperature by dynamic light scattering using a Nanosizer ZS90. Gel retardation assay was 
preformed to assure efficient compaction of the plasmid DNA at different N/P ratios. 
Stability of gene vectors 
All the gene carriers were investigated for their stability in biological fluids by dispersing 
them in 1X PBS and measuring their size at appropriate time points such as 10mins, 30mins, 1hr, 
2hrs, 4 hrs and 12 hrs. At each time point 10µL of the sample was drawn and diluted with 990µL 
of PBS and immediately sized for their stability. 
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3.6. In vitro experiments in human retinal pigment epithelial cells 
3.6.1. Cell culture 
The human retinal pigment epithelial cell line (ARPE-19) was a kind gift from Dr. 
Gerard Lutty, Wilmer Eye Institute. Cells were cultured in Dulbecco’s modified Eagle’s 
medium, low glucose, pyruvate (DMEM, Life technologies, Grand Island, NY) supplemented 
with 1% penicillin/streptomycin (Invitrogen Corp., Carlsbad, CA) and 10% heat inactivated fetal 
bovine serum (FBS, Invitrogen Corp., Carlsbad, CA). 
3.6.3. Evaluation of gene vector toxicity 
For the assessment of gene vector toxicity, cells were seeded in 96-well plates at an initial 
concentration of 1.0 × 104 cells/well and incubated at 37 °C. After 24 h, cells were incubated 
with a range of doses of DNA gene vectors in media for 24 h at 37 °C. Cell viability was 
assessed using the Dojindo cell counting kit-8 (Dojindo Molecular Technologies, Inc., Rockville, 
MD). Absorbance at 450 nm was measured using the Synergy Mx Multi-Mode Microplate 
Reader (Biotek, Instruments Inc., Winooski, VT). 
3.6.3. Transfection studies in RPE cells 
To assess cell transfection, cells were seeded in 24-well plates at an initial concentration 
of 5.0 × 104 cells/well. After 24 h, cells were incubated with different dendrimer-based gene 
vectors carrying pBAL plasmid (2 μg of DNA/well) in media for 5 h at 37°C. Subsequently, 
culture media was replaced with fresh media. After additional 3 days of incubation at 37°C, 
media was removed and 0.5 mL of 1X Reporter Lysis Buffer was added. Cells were subjected to 
two freeze-and-thaw cycles to assure complete cell lysis, and supernatants were isolated by 
65 
 
centrifugation. Luciferase activity in the supernatant was measured using a luciferase assay kit 
(Promega, Madison, WI) and a 20/20n luminometer (Turner Biosystems, Sunnyvale, CA). The 
relative light unit (RLU) was normalized to the total protein concentration of each well measured 
by the BCA protein assay kit (Thermo Scientific, Rockford, IL). Similarly, for image-based 
assessment of transfection cells were incubated with different dendrimer-based gene vectors 
carrying pEGFP plasmid. Two days after additional incubation at 37°C, cells were stained with 
NucBlue® Fixed Cell ReadyProbes® Reagent (Life Technologies, Grand Island, NY) and 
immediately imaged for fluorescence originated from NucBlue® and eGFP using confocal LSM 
710 microscope (Carl Zeiss, Hertfordshire, UK). 
3.6.4. Cell uptake studies by flow cytometry 
Cell uptake was assessed via flow cytometric analysis. Cells were seeded in 24-well 
plates at an initial concentration of 5.0 × 104 cells/well. After 24 h, cells were incubated with 
various dendrimer-based gene vectors carrying Cy5-labeled plasmid (2 μg DNA/well). After 5 h 
of incubation, the media was removed and cells were washed 3 times with 1x PBS and incubated 
with 1 volume of 0.25 % Trypsin with EDTA for 5 min at 37 °C. Two volumes of DMEM 
medium with 10% FBS were added to neutralize trypsin. The cellular uptake of gene vectors was 
measured using the Accuri C6 flow cytometer (BD Biosciences, San Jose, CA) with an FL4 
band-pass filter with emission detection wavelength of 675/25 nm. Data were analyzed using the 
BD Accuri C6 software. The thresholds were set using untreated samples; cellular uptake of 
dendrimer-based gene vectors was compared to that of free plasmid uptake.  
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3.6.5. Cell uptake evaluation by con-focal microscopy 
Similarly, for image-based analysis of gene vector cellular uptake; gene vectors 
formulated from BiD-TA-Cy5 and Cy3-labeled plasmid were administered to cells cultured in a 
35 mm glass bottom culture dish (MatTek Corporation, Ashland, MA) stained with NucBlue® 
Fixed Cell ReadyProbes® Reagent and imaged using confocal LSM 710 microscope over 12 h in 
a live cell imaging chamber.  
3.7. Results and Discussion 
3.7.1 Preparation and characterization of the bifunctional dendrimer (BiD, 2) 
The preparation of the bifunctional dendrimer (BiD, 2) was prepared using Fmoc 
protection/deprotection chemistry as shown in Figure 18A [134]. Our aim was to functionalize 
the dendrimer with approximately 20 amine groups out of the 64 hydroxyl end groups, so that it 
could be efficiently complexed with plasmid DNA. In brief, Fmoc-GABA-OH was reacted with 
the G4-OH dendrimer using PyBOP as a coupling reagent, to get Fmoc-functionalized 
intermediate (BiD-Fmoc, 1). A multiplet at 1.63 ppm for GABA-linker CH2 protons and 
multiplets between 7.30-7.86 for aromatic Fmoc protons in NMR confirmed the formation of the 
bond (Figure 19). The characteristic peak at 3.99 ppm for internal CH2 protons of G4-OH 
confirmed the formation of an ester bond with the linker. We calculated the loading of the linker 
by comparing the amidic protons of the dendrimer with aliphatic methylene protons of the linker, 
which suggested that 33 molecules were attached to the dendrimer (Figure 19). We carried out 
the deprotection step with piperidine (20% in DMF) without further purifying the intermediate, 
to get free bifunctional dendrimers (BiD, 2). Absence of Fmoc aromatic proton peaks in NMR 
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confirmed the deprotection of Fmoc groups. Using the proton integration method, we calculated 
that 18-20 linker molecules were attached to the dendrimer. 
 
Figure 18: Preparation of the dendrimer conjugates. (A) Preparation of the amine functionalized bifunctional 
dendrimer (BiD, 2); Bifunctional triamcinolone acetonide (BiD-TA, 4); and Cy5-labeled bifunctional triamcinolone 
acetonide (BiD-TA-Cy5, 5). (B) Preparation of triamcinolone acetonide-21-glutarate (TA-Linker). (C) Preparation 
of PEGylated amine functionalized PAMAM dendrimer (D-NH2-PEG, 6).  
 
 
Figure 19: Proton NMR characterization of BiD-FMOC conjugate 
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3.7.2 Preparation of bifunctional-TA conjugate (BiD-TA, 4) 
Synthesis of BiD-TA was performed using a three-step process with glutaric acid as a 
spacer, starting from G4-OH (Figure 18A). The Fmoc-functionalized dendrimer was reacted 
with TA-linker using PyBOP as the coupling reagent and DIEA as the base to get BiD-Fmoc-TA 
(3). The conjugate was characterized by 1H NMR and reverse phase HPLC. In the 1H NMR 
spectrum, peaks at 0.84-1.50 ppm represent methyl protons of TA, and peaks at 4.75-6.25 ppm 
represent aromatic protons of TA and along with dendrimer peaks confirmed the formation of the 
conjugate. Four multiplets belonging to Fmoc aromatic protons still remained in the spectrum 
between 7.29 to 7.86 ppm, confirming the presence of Fmoc-linker molecules. The payload of 
TA to the surface of the dendrimer was calculated by comparing the proton integration of the 
amide protons of the G4-OH to the aromatic proton of TA; approximately 10 molecules of TA 
were conjugated (Figure 20). Finally, the Fmoc groups were deprotected with piperidine (20% 
in DMF) to get bifunctional-TA dendrimer (BiD-TA, 4) and the structure was established in 
proton NMR. Absence of aromatic Fmoc protons signal in NMR and presence of all signals 
related to TA confirmed the formation of the product with free amines on the surface. In the final 
BiD-TA conjugate, 8 molecules of TA and 23 free amine groups were confirmed using the 
proton integration method (Figure 21). The lower number of TA and amine groups in the 
conjugate were due to hydrolysis of the ester bond with prolonged exposure to dialysis in DMF 
under basic conditions (presence of piperidine in the reaction mixture and traces of water in 
DMF). The BiD-TA conjugate was readily soluble in PBS buffer and saline solution, in contrast 
to TA which has poor water solubility. The retention time of BiD-TA in HPLC chromatogram at 
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20.1 min (monitored at 240 nm, PDA detector) confirms the conjugation of the TA to the 
dendrimer. At the same time, the retention time of BiD was 9.5 min (monitored at 210 nm). 
 
Figure 20: 1H NMR spectrum of Fmoc-functionalized bifunctional-triamcinolone acetonide (BiD-Fmoc-TA, 3) in 
DMSO-d6. 
 
 
Figure 21: 1H NMR spectrum of bifunctional-triamcinolone acetonide (BiD-TA, 4) in DMSO-d6. 
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3.7.3. Preparation of BiD-TA-Cy5 (5) conjugate 
The BiD-TA (4) was labeled with Cy5, a near IR imaging agent, to study the 
internalization of the conjugate in RPE cells. We have previously reported the preparation of the 
dendrimer-Cy5 and characterized extensively using HPLC/GPC, NMR and fluorescence 
spectroscopy.49 In brief, Cy5-mono-NHS ester was reacted with TA-functionalized bifunctional 
dendrimer (BiD-TA) in borate buffer to get Cy5-labeled dendrimers BiD-TA-Cy5 as shown in 
Fig. 1A. The final conjugate was purified by dialysis followed by GPC fractionation and 
characterized by reverse-phase HPLC and fluorescence spectroscopy. The HPLC trace showed a 
peak at 20.4 min. for BiD-TA-Cy5 (monitored at 645 nm excitation) different from BiD-TA and 
Cy5, confirming the formation of the conjugate. The fluorescence spectrum showed peaks at 648 
nm (for excitation) and 663 nm (for emission) which follow a similar pattern to Cy5 also 
suggesting the conjugation of Cy5 to the dendrimer. Only one mole equivalent of Cy5 was used 
in each reaction and the percentage payload of the Cy5 to the dendrimer is ~4-5 wt%. The 
fluorescence quantum yield for the final conjugate was calculated to be 0.18, demonstrating a 
slight decrease compared to free Cy5 (~0.28). 
3.7.6 Preparation of D-NH2-PEG (6) conjugate 
The amine functionalized dendrimer (D-NH2) was partially functionalized with 2K PEG 
to enhance the transfection efficiency of the dendrimer. In brief, NHS-ester of mPEG2000 was 
reacted with D-NH2 dissolved in borate buffer to get the PEG functionalized dendrimer and was 
characterized by proton NMR. In the NMR chart, a peak at 3.25 ppm corresponds to OCH3 peak 
of the PEG and multiplets between 3.36-3.66 ppm (methylene protons of PEG) along with 
dendrimer protons peaks in between 2.15-3.10 ppm confirm the formation of the conjugate. The 
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loading of the PEG to the dendrimer was calculated by comparing the amidic protons of the 
dendrimer (8.02-8.24) to the backbone methylene protons of the PEG and found out that 7 
molecules of the PEG were conjugated to the dendrimer. 
3.7.7. Surface charge of dendrimer conjugates 
BiD-TA and BiD ζ-potential were measured to be 13.9 mV and 12.9 mV, respectively. 
Their surface charge was significantly lower than the ζ-potential of D-NH2 (22.2 mV). D-NH2-
PEG demonstrated significant shielding of the D-NH2 positive surface charge resulting in a ζ-
potential of 11.7 mV. 
3.7.8. Dendrimer conjugates buffering capacity 
 As expected, BiD-TA and BiD demonstrated significantly lower buffering capacity in 
comparison to D-NH2 and PEI, suggesting limited ability to buffer the lysosome environment 
and achieve endosome escape through the proton buffer effect, hence, underlying the importance 
of the incorporation of TA in order to improve the nuclear localization and transfection 
efficiency (Figure 22). 
 
Figure 22: Buffering capacity. Measurement of buffering capacity of dendrimer base polymers by acid titration; 
PEI and ultrapure water were used as a control and solutions were titrated from pH 12 to pH 2 using 0.1 M HCL. 
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3.7.9. Gene vector formulation and characterization 
Using BiD as a base, we were able to formulate compact ~50 nm gene vectors with a 
nearly homogeneous size distribution (PDI: 0.16) (Figure 23A). Similarly, the conjugation of 8 
TA molecules did not appear to affect the complexation efficiency of these gene vectors, 
resulting in BiD-TA particles of similar size (~44 nm). We compared these gene vectors with 
conventional amine-terminated PAMAM dendrimer-based gene vectors at the same N/P ratio. 
This formulation resulted in particles with similar physicochemical characteristics (Figure 24 
and Table 2). We confirmed the spherical morphology and efficient plasmid compaction of 
these gene vectors using TEM (Figure 23B). The gene vectors were stable in an aqueous 
solution for at least 10 days (Figure 25A). However, once added into a high ionic strength 
solution (phosphate buffered saline, PBS), the particles rapidly aggregated and lost their colloidal 
stability. After one hour of incubation in PBS, BiD and BiD-TA reached a size of ~500 nm. D-
NH2 gene vectors aggregated at a slower rate and were ~300 nm in size at 1 hour (Figure 25B). 
To achieve successful transgene expression the gene vectors need to reach the target cells intact; 
the lack of stability and rapid aggregation imposes a serious obstacle to in vivo gene therapy. 
In order to improve nanoparticle stability we formulated gene vectors using a blend of BiD-TA 
and D-NH2-PEG.26 This technique resulted in gene vectors of similar size (~50 nm) but a 
significantly lower ζ-potential of ~6 mV in comparison to that of non-coated nanoparticles (BiD-
TA: ~11.4mV, BiD: ~13.3 mV, D-NH2: ~14.5 mV). The ratio of BiD-TA to D-NH2-PEG did 
not affect the physicochemical characteristics of the gene vectors. Gene vectors formulated by 
100% D-NH2-PEG had size of 42 nm and ζ-potential of 5.2 mV. In comparison, BiD-TA/ D-
NH2-PEG based gene vectors formulated with 25%, 50% and 75% of amines contributed by 
BiD-TA had sizes of 51 nm, 51 nm and 43 nm, respectively and ζ-potential of 7.3 mV, 6.1 mV 
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and 5.9 mv, respectively. The ‘shielding’ of the gene vectors ζ-potential suggests effective PEG 
coating. PEG significantly improved stability in high ionic strength solutions, as PEG coated 
gene vectors retained their physicochemical properties for at least 18 h. Interestingly, gene 
vectors with higher than 25% of amines contributed by D-NH2-PEG slightly increased in size, 
whereas gene vectors with only 25% of amines contributed by D-NH2-PEG retained their size 
over 18 h (Figure  25C). 
 
Figure 23: A schematic representation of gene vector formulations  
 
Table 2: Physicochemical characteristics of respective dendrimer-based gene vectors Size and polydispersity 
(PDI) were measured by dynamic light scattering (DLS). ζ-potential was measured by Laser Doppler anemometry. 
Measurements were performed in 10mM NaCl at pH 7.0 and are presented as average of at least 3 measurements ± 
standard error (SEM). 
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Figure 23: Gene vector characterization. (A) Hydrodynamic diameter distribution of respective gene vectors. (B) 
Transmission electron microscopy images of respective gene vectors in ultrapure water. 
 
 
Figure 24: Size and Zeta-potential of respective gene vectors measured by dynamic light scattering (DLS) method, 
data represents average of 3 measurements mean ±standard error. 
 
75 
 
 
Figure 25: Gene vector stability in ultrapure water (A) at high ionic strength solution (B) using DLS to measure 
hydrodynamic diameter. Data are presented as average of at least 3 measurements ± (SEM). 
 
3.9.10. Gene vector cell uptake and transfection efficiency in retinal pigment epithelium 
Transfection of BiD and BiD-TA was compared to D-NH2 gene vectors as well as PEI 
and PEG-PLL gene vectors, which are widely used and are considered to be gold standards for 
non-viral gene delivery [111, 141-143]. The use of BiD resulted in approximately 59-, 59000- 
and 29000- fold lower transfection efficiency in comparison to PEG-PLL, PEI and D-NH2 
respectively, in primary RPE cells. In contrast, incubation of BiD-TA gene vectors resulted in 
~1700- fold higher transfection in comparison to PEG-PLL, and no statistically significant 
difference in transgene expression in comparison to PEI or D-NH2. BiD-TA transfection 
efficiency was 100000-fold higher than BiD (Figure 24A), underlying the important role of TA 
in improving transfection efficiency. These results were qualitatively confirmed using eGFP 
plasmid in combination with fluorescence microscopy (Figure 24 C-D), which suggested that 
BiD-TA and D-NH2 were comparable.  
TA binds to the cytosolic glucocorticoid receptor (GR), which dilates the nuclear pores 
and translocate itself into the nucleus along with the gene carrier [132, 133].  Here, we take 
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advantage of the high concentration of GR in human ARPE cells to achieve high-level transgene 
expression using hydroxyl terminated PAMAM dendrimer-based gene vectors. 
 
Figure 24: Transfection of human ARPE-19 cells by cationic polymer based gene vectors. (A) Luciferase 
activity following in vitro delivery of the luciferase gene to human ARPE 19 cells with respective gene vectors. Data 
represents mean ± SEM. * denotes statistical significance; p<0.05 (B-D) In vitro eGFP expression by ARPE cells 
following eGFP plasmid delivery using respective gene vectors.  
 
Flow cytometry analysis was performed to assess the effect of different dendrimer types 
as well as the addition of TA on the gene vector cell uptake. BiD did not efficiently penetrate 
ARPE cells, with only ~30% of cell population taking up the fluorescently labeled plasmid, ~2.4-
fold lower than D-NH2. The mean fluorescence intensity (MFI) of the BiD treated cells was 100-
fold lower than D-NH2 treated cells. In contrast, BiD-TA based gene vectors achieved high level 
cell uptake of ~80%, comparable to D-NH2. However, the MFI, indicative of the absolute 
amount of plasmid taken up, was 5-fold lower than D-NH2 treated cells (Figure 25A-E). This is 
the first study to demonstrate not only improved transfection but also enhanced cellular uptake of 
TA conjugated gene vectors. 
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In order to confirm that the nanoparticles were able to enter the cells intact, we formulated BiD-
TA gene vectors with 5% of amines contributed by Bi-D-Cy5 and Cy3-labeled plasmid. 
Fluorescence confocal microscopy and differential interference contrast (DIC) microscopy were 
combined to observe co-localized Cy3-plasmid and Cy5-dendrimer in the cell cytoplasm as well 
as the cell nucleus, indicating that dendrimer nanoparticles were able to be taken up and localize 
in the nucleus intact (Figure 25F), without disintegration during the endocytotic, and 
endosomal-lysosomal-nucleus transport.  
 
Figure 25: Gene vector uptake by human ARPE cells. (A-E) Flow cytometric analysis of fluorescently labeled 
gene vector cell uptake after 4 h of incubation with respective gene vectors. Data represents mean ± SEM. * denotes 
statistical significance; p<0.05 (F) Confocal imaging of BiD-TA gene vector cell uptake using dual fluorescent 
labeling. Dendrimer (Green), Plasmid (Red), Co-localization (Yellow). White arrow indicates gene vectors in the 
cytoplasm; white arrow head indicates gene vectors in the nucleus. 
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3.7.11. Role of TA and PEG in cell uptake and transfection efficiency 
In order to further understand the amount of TA required for effective cell uptake and 
transgene delivery, we repeated the cell uptake and transfection studies using dendrimer 
nanoparticles formulated from a blend of BiD-TA and BiD at a decreasing percent of amines 
contributed by BiD-TA (Figure 26A-H). Varying the BiD-TA to BiD ratio did not result in 
significant change of the gene vector physicochemical characteristics. More specifically, 
formulation of nanoparticles with 100%, 75%, 50%, 25%, 10% and 5% of amines contributed by 
D-TA resulted in sizes of 42.9 nm, 34 nm, 34.5 nm, 38.8 nm, 46.2 nm and 45.8 nm, respectively. 
Also, the ζ-potentials were 16.5 mV, 9.92 mV, 15.8 mV, 13.6 mV, 15.3 mV, 16.9 mV, 
respectively.  
 
Figure 26: Effect of conjugated TA on gene vector cell uptake and transgene expression. (A-H) Flow 
cytometric analysis of cell uptake of fluorescently labeled gene vectors with varying ratios of BiD-TA/BiD. (I) 
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Luciferase activity following in vitro delivery of luciferase gene to human ARPE 19 cells with respective gene 
vectors of varying BiD-TA/BiD ratios. Data represents mean ± SEM. 
 
Both the percentage of cell uptake as well as MFI demonstrated a positive correlation 
with the percentage of BiD-TA in the gene vectors (R2: 0.842, p<0.01; R2: 0.923, p<0.01; 
respectively). The transgene expression demonstrated a similar positive correlation (R2: 0.765, 
p<0.01). Importantly, the inclusion of BiD-TA equal to or lower than 10% did not seem to 
improve transfection over BiD gene vectors. This underlines the importance of achieving a 
significant TA concentration on the gene vector surface in order to allow for improvement of cell 
uptake and transgene expression. 
Having established the role of a PEG coating in drastically improving the stability of 
these gene vectors we attempted to determine the effect of formulating a gene vector with a 
blend of D-NH2-PEG and BID-TA on cell uptake and transfection efficiency. We used a 
previously established blending technique, with different percentages of amines contributed by 
D-NH2-PEG, and achieved effective PEG coating of the gene vectors as demonstrated by the 
significant shielding of the positive surface charge and stability of the gene carriers. Flow 
cytometric analysis determined no significant difference in percentage of cell uptake or MFI 
between PEG coated gene vectors with varying ratios of D-NH2-PEG to BiD-TA (Figure 27A-
E). The percentage of cell uptake of the PEGylated dendrimer gene vector did not differ 
significantly from BiD-TA and D-NH2 gene vector uptake (~80%). However, the MFI was 
significantly lower for the PEGylated gene vectors (p<0.05), indicating lower absolute amount of 
gene vector uptake. No difference in transfection efficacy was observed between the PEGylated 
gene vectors. The transgene expression following incubation with PEGylated gene vectors was 
significantly decreased compared to BiD-TA and D-NH2 (p<0.05) but still significantly higher 
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than BiD-based gene vectors (p<0.05) (Figure 17F). These findings are in good agreement with 
previous studies demonstrating that relatively small nanoparticles can be efficiently taken up 
regardless of their PEGylation profile. However, the improved stability of PEG coated cationic 
polymer based gene vectors impedes endosome escape and reduces transfection [143]. 
 
Figure 27: Effect of BiD-TA gene vector PEG coating on uptake and transgene expression. (A-H) Flow 
cytometry analysis of cell uptake of fluorescently labeled gene vectors with varying D-NH2-PEG/BiD-TA ratio. (I) 
Luciferase activity following in vitro delivery of luciferase gene to human ARPE 19 cells with respective gene 
vectors of varying D-NH2-PEG/BiD-TA ratio. Data represents mean ± SEM. 
 
3.7.12. Cytotoxicity profile 
ARPE cell transfection has been greatly limited by the cytotoxic effect of different gene 
vector systems. Importantly, cell incubation with varying concentrations of BiD-TA, BiD and 
BiD-TA/D-NH2-PEG blend did not result in significant toxicity. However, incubation with D-
NH2, D-NH2-PEG and BiD-TA/D-NH2 blend resulted in statistically significant toxicity, 
presumably due to the increased positive surface charge and cytotoxicity of the base polymers 
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(Figure 28). Therefore, partial PEGylation and the hydroxyl groups improves the toxicity profile 
of the delivery vectors. 
 
Figure 28: Cytotoxicity of dendrimer-based gene vectors to human aRPE cells. Cells were treated with varying 
concentrations of respective gene vectors. Cell viability was measured after 24 h of treatment and compared to non-
treated controls. Data represents the mean ± SEM. * Denotes statistically significant (p < 0.05) difference from 80%. 
 
3.8. Conclusions 
In this study we attempted to address the inherent limitations of cationic-polymer based 
non-viral gene vectors. Using hydroxyl-functionalized PAMAM dendrimers, we achieved 
effective plasmid compaction, resulting in relatively small complexes using (a) a base-polymer 
with minimal amount of primary amine groups to minimize cytotoxicity, (b) TA as a nuclear 
localization signal to improve transfection and (c) a hydrophilic and near neutral PEG coating to 
improve stability in physiological solutions. We demonstrated efficient transgene delivery in 
hard to transfect human retinal pigment epithelial cells. 
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Cationic polymers with a high number of amine groups, such as PEI and amine-terminated 
PAMAM dendrimers, have traditionally been used for efficient complexation [112]. We 
establish a new approach in which we minimally functionalized a hydroxyl PAMAM dendrimer, 
with or without the conjugation of TA, in order to achieve efficient compaction while retaining a 
reduced cytotoxicity profile in primary RPE cells [144]. These complexes demonstrate 
physicochemical characteristics similar to conventional D-NH2 gene vectors. However, the lack 
of stability of both conventional and BiD based gene vectors in high ionic strength solutions 
somewhat limits their translational relevance. For this reason, we adapted a previously 
established blending technique [113]. to introduce a hydrophilic PEG coating which substantially 
reduces aggregation of the particles and increases the possibility of reaching the target cells 
intact [117,118] allowing for protection of the plasmid cargo [154] and more efficient cell 
uptake. 
TA has previously demonstrated the ability to improve transgene expression and nuclear 
localization in human embryonic kidney and human hepatocellular carcinoma [132-133]. In this 
study we used this attribute in order to offset the lack of buffering capacity, endosome escape 
and nuclear localization of BiD-based gene vectors and improve transgene expression in primary 
RPE cells, an important group of cells in retinal function and retinal diseases. Indeed, BiD-TA 
based gene vectors were observed to enter the nucleus intact and achieved high level transgene 
expression similar to conventional D-NH2 based gene vectors. We demonstrate for the first time 
that TA can drastically enhance transfection of hard to transfect retinal pigment epithelial cells. 
We further show that the effect of TA is dose dependent and that at least 25% of base-polymer 
needs to be conjugated to TA to significantly improve transgene delivery.  
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 The ability of gene vectors to enter the cells constitutes an important limiting factor for 
non-viral gene delivery for slowly replicating cells. We found that BiD based gene vectors are 
taken up significantly less than D-NH2 gene vectors, presumably due to reduced electrostatic 
interaction with the cell membrane. Interestingly, TA seems to be involved in the endocytosis 
process as there was a significant improvement in cell uptake for BiD-TA based gene vectors. In 
fact, there was a positive correlation between the amount of TA on nanoparticles and cell uptake. 
This phenomenon may be attributed to the nuclear localization of BiD-TA gene vectors leading 
to decreased exocytosis [146]. 
 PEG coating has been suggested to reduce particle uptake by cells [147-148].  However, 
in good agreement with previous studies on PEGylated cationic polymer based gene vectors 
[143], we found that PEGylation did not affect cellular uptake. Their small particle size may 
contribute to effective uptake in spite of PEGylation [149-150]. The reduced transfection 
efficacy of the PEGylated gene vectors may be explained by their improved stability that 
impedes DNA unpackaging and endosome escape [143, 151]. The stability in physiological 
solutions, favorable safety profile and relatively high transfection efficiency of these PEGylated 
gene vectors renders them a promising vehicle for the delivery of therapeutic transgenes to 
retinal pigment epithelial cells in vivo. 
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CHAPTER 4 “EVALUATION OF RETINAL MICROGLIA UPTAKE AND 
BIODISTRIBUTION OF DENDRIMERS IN MICE ISCHEMIC-REPERFUSION (I/R) 
MODEL” 
4.1. Abstract 
 Microglial activation occurs in many diseases of the retina including viral infection, 
diabetes, and retinal degeneration. It was shown previously that hydroxyl-terminated 
polyamidoamine (PAMAM) dendrimers are taken up and retained in microglia during retinal 
degeneration. The purpose of this study was to develop a nanoparticle formulation that targets 
activated retinal microglia and can be delivered safely intravenously as well as intravitreally. The 
dendrimers were conjugated to Cy5 (D-Cy5) and were evaluated by intravenous (femoral vein) 
or intravitreal injection in normal BALB/c mice and in a murine model of ischemia/reperfusion 
(I/R). Uptake of the dendrimer by microglia was determined with immunofluorescence using 
rabbit Iba-1 antibody with Cy3-goat anti-rabbit secondary antibody (microglia) and GSA lectin-
FITC (blood vessels and microglia). Clearance of the D-Cy5 from the normal eyes appeared 
almost complete by 24 hours after injection. In eyes with activated microglia after I/R injury, the 
D-Cy5 appeared to be retained by microglia (IBA+) up to 21 days after intravenous 
administration. The nontoxic PAMAM dendrimers appeared to be an excellent drug delivery 
system to activated microglia. This approach may yield an intravenous dendrimer-based therapy 
to decrease inflammation in diseases associated with retinal microglia activation like age-related 
macular degeneration. 
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4.2. Introduction 
Microglia cells are the resident inflammatory cells of the brain and retina [152]. They 
become activated in diseases such as diabetes and retinal degeneration where photoreceptors die, 
causing microglia to scavenge dead cells. Activation of retinal microglia occurs in a mouse 
model of Ischemia reperfusion (I/R) which is a model of branch vein occlusion. Retinal vascular 
occlusion, be it by high intra-ocular pressure in I/R model or thrombus in BVO, causes a 
decrease in blood flow to the eye or ischemia. This causes death of photoreceptors initiating 
further activation of inflammatory microglia [153].  
Dendrimers are a group of molecules that have the potential to deliver drugs and small 
molecule therapies to intracellular domains because of the large number of functional groups. 
Previously our group have shown utility of a dendrimer-based therapeutic can be used to treat a 
rabbit model cerebral palsy (CP. This rabbit model replicates the neuroinflammation seen in the 
adult brain. Using microglia as a target for attenuation of inflammation may be an alternative 
way for treating a number of diseases of the brain and eye such as age related macular 
degeneration (AMD) where inflammation plays a large part in the degeneration of 
photoreceptors which destroys the delicate environment of the retina and choroid [27]. 
Therefore, we in this chapter investigated the ability of dendrimers to target activated 
microglia in retina. We evaluated dendrimeric transport into normal murine retina as well as 
retina following ischemia reperfusion injury in which microglia activation occurs. This study 
also aimed to characterize the transport and retention of dendrimer by microglia in the retina 
after local intravitreal delivery as well as systemic intravenous delivery. Systemic delivery would 
have many advantages to current treatments as there are at present no systemic treatments 
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available for ischemic retinopathies and AMD. These advantages include less frequent injections 
due to retention in microglia and ability to delivery systemically, avoiding monthly intraocular 
injections as in current anti-VEGF therapies. 
4.3. Materials and methods 
4.3.1. Synthesis of D-Cy5 conjugates: 
D-Cy5 was synthesized in 3 steps reaction. 1st step is synthesis of bifunctional dendrimer 
using FMOC-NH-Caproic acid to G4-OH dendrimer using PyBOP as coupling reagent with 
DIEA as base. The FMOC groups are deprotected using piprideine in the 2nd step and reacted 
with Cynine due Cy5-NHS ester. The resulted conjugates were purified using dialysis against 
DMA and then against water. The purified conjugate solution was lyophilized and then passed 
through GPC to remove traces of unreactive dye.     
4.3.2. High Performance Liquid Chromatography (HPLC) analysis 
The purity of the dendrimer-Cy5 conjugates (D-Cy5) were analyzed using Waters HPLC 
instrument equipped with Waters In-line degasser, binary pump, photodiode array (PDA) 
detector, multi fluorescence λ detector and auto sampler (maintained at 4ºC) interfaced with 
Empower software. The HPLC chromatogram was monitored simultaneously for absorbance at 
210 nm for dendrimer and 650nm for Cy5 using Waters 2998 PDA detector and fluorescence 
with excitation at 645 nm and emission at 662 nm using Waters 2475 fluorescence detector. The 
water/acetonitrile (0.1% w/w TFA) was freshly prepared, filtered, degassed, and used as a 
mobile phase. TSK-Gel ODS-80 Ts (250 X 4.6 mm, 25 cm length with 5 µm particle size) 
connected to TSK-Gel guard column was used. A gradient flow was used with initial condition 
of 90:10 (H2O/ACN) and gradually increasing the acetonitrile concentration at 10:90 
87 
 
(H2O/ACN) by 30 min and returning to original initial condition 90:10 (H2O/ACN) in 60 min 
with flow rate of 1 ml/min. 
4.3.3. Dynamic light scattering and Zeta potential analysis:  
The particle size and ζ-potential of G4-OH and D-Cy5 conjugates were determined by 
dynamic light scattering (DLS) using a Zetasizer Nano ZS  equipped with a 50 mW He-Ne laser 
(633 nm). For sizing the samples were dissolved in deionized water (18.2 Ω) to make the 
solution with the final concentration of 50 µg/mL. The solution was filtered through a cellulose 
acetate membrane (0.45 micron, PALL Life Science) and DLS measurements were performed at 
25°C with a scattering angle of 173°. Zeta potentials were calculated using the Smolokowsky 
model and measurements were performed in triplicate. 
4.3.4. Animals & Ischemia reperfusion (I/R) injury: 
All procedures involving the animals conformed to the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research. BALB/c albino mice, each weighing ~25 grams, 
housed in wilmer animal facility at johns hopkins were used for transport as well as I/R studies. 
All surgeries were performed under anesthesia using ketamine (100mg/Kg) and Xylazine 
(10mg/Kg) injected into the peritoneal space. Six mice were used in each group at each time 
point.  I/R injury was performed in left eye by following the procedure described elsewhere [7]. 
Briefly, the anterior chamber was cannulated with 30 gauze needle attached with line infusing 
saline system. The saline system is mounted on to a custom made saline reservoir and elevated to 
certain height (calibrated to 90mm Hg). The IOP was elevated to 90mm Hg for 90mins and I/R 
injury and shut off of choroidal circulation was evidenced by blanching of the posterior segment 
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via fundus examination. After ischemia the needle is immediately withdrawn for immediate 
blood reperfusion. The right eye with no injury serves as control. 
4.3.5. Routes of Administration, Injections and Time points for Sacrifice 
Dendrimer-Cy5 (D-Cy5), free Cy5 (free dye) or PBS was injected 6 days after Ischemia 
reperfusion injury (I/R) by intravitreal administration or intravenous administration. For 
intravenous injections, 100 µl of D-Cy5, Cy5 or PBS was injected into the femoral vein of the 
mouse using a 1ml syringe. Each mouse injected via femoral vein on a D-Cy5 basis in 100 µL of 
sterile PBS (600 µg). For intravitreal injections, 2 µl (20 µg) of D-Cy5, Cy5 or PBS was injected 
with a Harvard compression injector using a glass needle. A 30 gauge metal needle was used to 
pierce a hole to allow the glass needle into vitreous chamber. Animals were sacrificed at 24 
hours, 72hours or 21 days after injection of D-Cy5. Control animals (Cy-5 and PBS) were 
sacrificed at 24 hours post administration. Animals were sacrificed with a lethal dose of 
pentobarbital intracardially after ketamine/Xylazine anesthesia. 
4.3.6. Biodistribution analysis of D-Cy5 in vital organs and posterior eye cups 
Twelve BALB-C mice weighing ~ 25 gr BW were used for this study. Four animals were 
sacrificed at each time point: 24hrs, 72hrs and 21 days. Each mouse was injected via femoral 
vein with 600 µg of D-Cy5 in 100 µL of sterile PBS. At respective time point, the animals were 
euthanized and vital organs (heart, lungs, spleen, kidney, liver and eyes) were harvested 
immediately and respective wet organ wet weights were noted, organs snap frozen on dry ice, 
and stored at -80ºC until analysis. Upon analysis, the tissues were thawed and approximately 
100-150 mg of tissue were measured and homogenized with 1 ml of MeOH in low DNA binding 
using stainless steel bead and tissue homogenizer resulting in a pulpy tissue suspension. The 
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suspension was sonicated for 30 minutes and appropriate volumes containing 100mg of tissue 
were placed in different low DNA binding vials and diluted with methanol to 1 ml so that the 
same amount of tissue and same volume was analyzed for each sample. The samples were 
centrifuged at 10,000 rpm for 10 mins at 4ºC resulting in supernatants, which were subjected to 
fluorescence spectroscopy (FLS).    
4.3.7. Analysis of cryopreserved tissue sections and microglia localization 
Eyes were enucleated and fixed in 2% paraformaldehyde (PFA). The anterior chamber of 
the eye was removed and eye cup cryopreserved using previously established protocols. The eyes 
were frozen with dry ice in isopentane in 20% sucrose with optimum cutting temperature 
compound (OCT) in a 1:2 ratio respectively. Cryoblocks are stored at -80°C until sectioned. 8um 
sections were cut from previously frozen blocks using a cryostat. Sections were incubated in 
rabbit anti-Ionized Calcium Binding Adapter 1 molecule (IBA-1), which is a microglia cell 
marker, and a goat anti-rabbit-Cy3 secondary antibody applied. Sections were analyzed on a 
Zeiss 510 confocal microscope.  Excitation and emission wavelengths and laser settings were 
identical to analyze all tissue in Intravitreal injected animals and IV injected animals. A z-stack 
of the sections were taken and collapsed to give an image through the depth of the whole section. 
To quantify the amount of D-Cy5 accumulation in retina and choroid upon intravenous 
and intravitreal injections were determined as follows. The anterior chamber along with the lens 
were removed from the enucleated eyes and the posterior eyecups were frozen using liquid 
nitrogen and immediately homogenized using disposable micro pestles ( Bel-art, NJ, USA.) and 
reconstituted with 100µL of 0.05M Methanolic tichloroacetic acid (TCA) and sonicated for 
15mins. The methanol was evaporated using vacuum and the homogenized tissue was 
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reconstituted with 100µL of PBS and freezed at -80ºC and lyophilized. The white powder 
obtained was reconstituted with 100µL of HPLC grade methanol and sonicated for 20 mins and 
centrifuged at 20,000 rpm for 20 mins. The supernatant was collected and subjected to FLS 
measurements using low volume quartz cuvette (starna cells. Inc., CA, USA). The fluorescent 
emission values were obtained with a slit width 10-10 at 665nm and the background was 
subtracted from PBS injected samples. The amount of D-Cy5 was calculated from calibration 
graph ranging from 0.5 to 20ng at same slit width.   
4.4 Results 
4.4.1. Synthesis of D-Cy5 Conjugates 
Ethylenediamine-core poly-(amidoamine) [PAMAM] hydroxyl-terminated generation-4 
(G4-OH) were labelled with near IR fluorescent dye Cy5 which was already reported in our 
previous publications [72]. Briefly, G4-OH was partially functionalized by 6-amino caproic acid 
using FMOC protection/deprotection chemistry resulting in bifunctional dendrimers with ~5-6 
NH2 groups on their surface. The resulting bifunctional dendrimers with reactive amine groups 
were reacted with N-hydroxysuccinimide monoester Cy5 dye to obtain the D-Cy5 conjugate 
(Figure 29). The resulting conjugates were purified using dialysis and GPC and characterized 
using 1H NMR.   The HPLC chromatogram of bifunctional dendrimer showed elution time of 
14.84 min from the column which is different from the elution time of G4-OH dendrimer 
(elution time 14.42 min) (Figure 30). This indicates formation of new compound and there is a 
minor shift in elution time indicating that the structural property of G4-OH dendrimer has not 
changed significantly.  
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Figure 29: Preparation of Cy5 labelled PAMAM G4 dendrimer (D-Cy5) 
 
Figure 30: HPLC chromatrograms of G4-OH, Bifunctional dendrimer, D-Cy5 and free Cy5 eluted from the 
columns. Appearance of different peaks at varied time points assures the purity of the conjugates. 
 
This is also congruent from the DLS results where the approximate size and Zeta 
potential of G4-OH dendrimer 4.36±0.18nm and +4.59±0.11mVrespectively. Whereas, the size 
and Zeta potential values of bifunctional dendrimer were 4.87±0.20 and 6.63±0.24mV 
respectively indicating no significant change in size and surface properties of dendrimers. 
Appearance of new peak simultaneously in 16.69min at 647nm (UV λmax for Cy5) and 645nm 
(fluorescence emission of Cy5) which is different from the Cy5 peaks (20.39min) confirms 
successful conjugation of dye to the dendrimers. 
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4.4.2. Changes in retinal microglia and retinal structure 
In normal retina Iba-1+ve resident microglia/macrophages were found to be lesser in 
number and have ramified morphology with distinctive dendritic structures. The heterogeneous 
populations of microglial cells were predominately found in choroid and inner nuclear layer 
(INL) and very few of them were found scattered in outer plexiform layer (OPL).  The retinas 
were structurally intact with all the layers compacted to one other. I/R injury led to a marked 
activation of microglia in the retina and choroid. In I/R retinas the microglial/macrophage cells 
showed marked changes in morphology, increased number and retinal distribution. 6 days post 
IR the retinal resident microglial/macrophages were devoid of their dendritic structures, became 
amoeboid with smaller cell bodies. Increased numbers in activated microglial cells were found 
distributed in all retinal layers such as IPL, INL, ONL and subretinal layers. Interestingly we 
found decreased number choroidal microglia/macrophages suggesting their infiltration in to 
retina. The IR injury caused collapse of inner retinal layers and retinal detachment from choroid 
and RPE layers. We also observed thinning of retina especially the nuclear layers in IR injured 
retinas when compared to normal retina suggesting neuronal and ganglionic cell atrophy (Figure 
31). 
 
Figure 31: Confocal images of normal and I/R retina. A) Normal retina with regular retinal layers and less 
microglial cells (Green). B) I/R retina showing pathology related structural alterations and damage with increased 
microglial population. (NFL- Nerve fiber layer, INL- Inner nuclear layer, ONL-Outer nuclear layer). 
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4.4.3. Retinal biodistribution of D-Cy5 upon intravitreal & intravenous administration: 
Upon, Intravitreal administration D-Cy5 showed differential biodistribution between 
normal and I/R retinas. In normal retinas 24hrs post Intravitreal injection of D-Cy5 yielded very 
minimal fluorescence in retina and choroid and we did not notice any fluorescence signal from 
D-Cy5 beyond 24 hrs time point indicating that dendrimers were cleared intact from retinas in 
later time points (72hrs and 21days). In the case of I/R injured retinas we observed significant 
fluorescence signal from D-Cy5 in retinal sections. At 24hrs post injection dendrimers (D-Cy5) 
were found co-localized in Iba-1 +ve microglial in subretinal space, outer nuclear layer (ONL), 
inner nuclear layer (INL) and in near vicinity of  internal limiting membrane (ILM) in retina. We 
have also observed dendrimers entrapment in vitreous network (yellow arrows) and localized in 
other cells throughout all retinal layers. At 72 hours post intravitreal injection of D-Cy5 were 
cleared out from other cells and vitreous network in I/R eyes (Figure 33 A-H). D-Cy5 was found 
co-localized and retained in microglia/macrophages near ILM, in inner retina, and sub-retinal 
space. This demonstrated by co-localisation of D-Cy5 (red) with IBA1 labelled cells (green) 
Interestingly, 21 days post injection D-Cy5 were found specifically retained and co-localized in 
microglial cells in photoreceptor layer, IPL and near ILM. However, in the case of free Cy5 
injected animals, both  I/R and normal eyes  Cy-5 can be seen in outer and inner retina and 
appears to be concentrated in blood vessels near the ILM be were completely cleared out after 
24hrs post injection (Figure 34).  
D-Cy5, Free Cy5 or PBS were injected intravenously through femoral vein 6 days later in 
age matched mice under gone I/R injury in one eye. At respective time points (24hrs, 72hrs and 
21 days) post injection the eyes were enucleated for qualitative assessment of differences in 
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retinal biodistribution of dendrimers between I/R injured and normal retina at different time 
points using IHC.  In I/R eyes at 24 hours post intravitreal D-Cy5 administration, D-Cy5 has 
made their entry in to retina from systemic circulation and was found co-localized concentrated 
in microglia posterior to the internal limiting membrane (ILM) in retina, outer nuclear layer 
(ONL) and subretinal space. IBA-1+ cells in the subretinal space, posterior to the outer nuclear 
layer (ONL) also had D-Cy5, However, both in normal and  I/R eyes 24 hours post free Cy5 dye 
administration, Cy-5 appears to be blood vessels specific and seen concentrated & entrapped in 
choriocapillaries  posterior to RPE layer and were cleared at later time points, suggesting that 
dendrimers can cross the outer retinal barrier were as free Cy5 cannot. Interestingly, we did not 
find any fluorescence signal from D-Cy5 indicating the intact blood retinal barrier. 
 
Figure 32. Sections from ischemia/reperfusion eyes 24 hours after intravitreal  injection. A-D. Dendrimer-Cy5 (red) 
is present in Iba-1+ microglia (green)(arrows).  E-H. Higher magnification of D-Cy5 (red) in Iba-1+ microglia.  I-L. 
Cy5 or free dye (red) is throughout inner retina and not associated with only Iba-1+ microglia (green). It appears to 
be associated with blood vessels in inner retina (arrows).  
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Figure 33: 72 hrs after intravitreal injection. A-D. D-Cy5 is still present in microglia in I/R eyes. E-H. Higher 
magnification of D-Cy5 in microglia (arrows) and RPE cells (arrowheads). I- L. D-Cy5 was not present in non-I/R 
control eyes. [DAPI nuclear counterstain (blue). Dendrimer-Cy5 (red). A-D and I-L 20X magnification; E-H 40X 
magnification]  
 
 
 
Figure 34: Twenty one days after intravitreal injection. A-D. D-Cy5 remains in Iba-1+ cells in I/R eyes (arrows). 
Some appear to be subretinal macrophages (left arrows). E-H. Retina of D-Cy5 injected eyes after I/R at higher 
magnification. I- L, D-Cy5 is not present in non-I/R control eyes. [DAPI nuclear marker (blue). Dendrimer-Cy5 and 
Cy5 (red). Iba-1 microglia cell marker (green). A-D and I-L 20X magnification; E-H 40X magnification] 
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72hrs post D-Cy5 injection intravenously, D-Cy5 were selectively localized and retained in 
microglia/macrophages in I/R retinas Even though activated microglial cells were scattered and 
distributed in all retinal layers but dendrimers were found retained only in microglial cells in 
choroid, subretinal/photoreceptor layer and inner nuclear layers (INL) At 21 day post injection 
D-Cy5 were retained in microglial cells which are present adjacent to inner limiting membrane 
(ILM),   there was relatively less microglial cells and D-Cy5 co-localization than compared to 
24hrs and 72hrs time point retinas.  
 
Figure 35: Sections of retinas from I/R eyes 24 hr after intravenous injection. A-D. D-Cy5 colocalizes Iba-1 labeled 
cells (green) in retina and also appears to be in RPE cells. Panel 2 A-D retinal section of non I/R eye showing D-
Cy5 uptaken by cgoroidal circulating macrophages but did not cross the BRB. I-L. Free Cy5 dye is still present in 
choroid after 24 hrs. M-P. There is no fluorescence in the Cy wavelength in eyes receiving PBS intravenously. 
[DAPI nuclear counterstain (blue); D-Cy5 and Cy5 (red); Iba-1 microglia cell marker (green). A-D and I-P 20X 
magnification; E-H 40X magnification] 
 
The microglial cells were seemed to revert back to their ramified morphology but also 
uptake and retention of D-cy5 in them continued to be concentrated in microglia in the choroid, 
sub-retinal space in I/R eyes at 72 hours post intravenous administration. In these areas, IBA1 
labelled cells (green) colocalized with D-Cy5 (red).There was little fluorescence at Cy5 
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wavelength in control non-I/R eyes 72 hours after intravenous injection of D-Cy5. D-Cy5 
appeared to have been cleared from the retina by 72 hrs. 
 
Figure 35: Retina 72 hours post intravenous D-Cy5 administration. A-D. There are many Iba-1+ cells in I/R retinas 
and a few in this field have D-Cy colocalized. E-H. Colocalization is shown at higher magnification. I- L, No cells 
have D-Cy5 in non-I/R control eyes. [DAPI nuclear counterstain (blue). Dendrimer-Cy5 and Cy5 (red). Iba-1 
microglia cell marker (green). A-D and I-L 20X; E-H 40X]. 
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Figure 36: Retina and choroid 21 days after D-Cy5 injection. A-D. I/R retina still has Cy-5 colocalized with an Iba-
1+ cell (arrow).. E-H. D-Cy5 colocalization with Iba-1 shown at higher magnification. I-L. D-Cy5 administration 
with non-I/R control eyes. A-H arrows mark colocalization of D-Cy5 (red) and Iba-1 labelled cells (green). [ DAPI 
nuclear marker (blue). Dendrimer-Cy5 and Cy5 (red). A-D and I-L 20X magnification; E-H 63X] 
 
4.4.4. Quantitative biodistribution of D-Cy5 in vital organs 
Quantitative biodistribution in vital organs (liver, kidney, spleen, heart, lungs and serum) 
and kinetics of D-Cy5 injected intravenously into animals with I/R injury was assessed using 
FLS method [154]. For analysis, weight of tissues was measured before being homogenized and 
D-Cy5 was extracted using methanol as described previously by Wojciech et al. [154]. The D-Cy 
conjugates were intact stable in human plasma at 37ºC and in vivo and also the applied methanol 
extraction protocol yielded best recovery of 96%. The methanol extracts were subjected to 
fluorescence measurements for emission values using fluorescence spectrophotometer. The 
amount of D-Cy5 accumulated in each organ was calculated by incorporating the emission 
values (subtracted background from emission values of respective organs injected with PBS) into 
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the calibration graphs and the values were then back calculated to % of injected dose (ID)/organ 
using whole organ wet weights.   
 Upon intravenous injection, some percentage of D-Cy5 was immediately cleared out 
from circulation via urine. We observed that the animals injected with D-Cy5 or free Cy5 
urinated deep blue urine within ~5-7 mins. Twenty four hrs post injection, the majority of D-Cy5 
was cleared from blood plasma but retained in differential amounts in vital organs (Figure 37A). 
At 24 hrs  
 
Figure 37: Biodistribution and accumulation of intravenously injected dendrimers. A) Biodistribution in vital 
organs. B) D-Cy5 fluorescence levels  in posterior eyecup in I/R and non I/R eyes via intravenous injection C) D-
Cy5 levels in posterior eye cup via intravitreal injections. 
 
according to FLS analysis ~0.18% of the injected dose was still in blood. The total blood volume 
for BALB/C mice is 10.35 ±0.16 ml/g of tissue. The injected D-Cy5 conjugates were cleared but 
some accumulated in the kidneys. This is in good agreement with the previous results based on 
fluorescence measurements and radiolabelling. The D-Cy5 biodistribution and accumulation is 
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as follows: kidney (29.98±2.5%), liver (11.19±2.2), and spleen (3.33±1.26) (Figure 37A). Heart 
and lungs had minimal accumulation of D-Cy5 (0.0049% and 0.01% respectively). Free Cy5 on 
other hand was found to be rapidly cleared from blood and had significantly lower accumulation 
of 0.82±2.93% of the injected dose (ID) in kidneys in 24 hrs. Moreover, we could not detect any 
fluorescent signals in other organs indicating the free Cy5 has rapid clearance. At 72 hrs post 
injection, D-Cy5 was cleared from heart, lungs, and spleen but found predominately and 
persistently retained in kidneys (5.53±1.5%) and to very little extent in liver (0.73±0.026%). Free 
Cy5 was not detectable in any of the organs indicating that they were either cleared from the 
body or the amount was below limits of detection (LOD). Twenty one days post injection, 
dendrimers were completely cleared from all organs examined.  
 
Figure 38: Qualitative assessment of D-Cy5 levels in the kidney as a function of time, using confocal microscopy. 
A-C. (top panel) cross sections of kidneys at 24 hrs, 72 hrs and 21 days respectively post D-Cy5 injection 
intravenously. D-Cy5 (red) upon intravenous injection were rapidly cleared from systemic circulation and found 
predominately accumulated in the proximal tubules of the kidney cortex and were excreted at later time points (72 
hrs & 21 days). Below are the HPLC chromatograms of the kidney extract proving the fluorescence signals from 
kidney cortex are from intact D-Cy5 (based on the retention time 14.92 min). Whereas the time increases the peak 
signal decreases indicating D-Cy5 excretion via urine and is in good agreement with the confocal images. 
 
Because there was predominant accumulation of D-Cy5 in kidneys, a qualitative 
microscopic analysis was done using confocal microscopy. At 24 hrs the signal intensity of D-
Cy5 channel was high in proximal tubules (Figure 28) of the kidney cortex but the signal 
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intensity was decreased in 72 hrs kidneys, which is in good agreement with the biodistribution 
data. The kidney extracts were also analysed using HPLC to confirm that the fluorescence 
emission is from D-Cy5 or free Cy5 species. The HPLC chromatograms of the kidney extracts at 
24 and 72 hrs showed a small peak from free Cy5 but the major fraction of the peak was D-Cy5 
Twelve % of the conjugated Cy5 was released, based on the calibration graphs of free Cy5, 
suggesting that the conjugates are somewhat intact in-vivo up to 72 hrs and is in good agreement 
with our previous studies [152]. The H and E analysis on these kidney sections show no 
neutrophil or monocyte infiltration, no structural damage or any signs of toxicity suggesting that 
the injected D-Cy5 dose did not inflict any toxic effects to organs 
4.4.5. Ocular biodistribution of D-Cy5 in retina and choroid 
In terms of the amount of D-Cy5 injected per animal, the intravenous dose was 30-fold 
higher than that of the intravitreal dose. Interestingly, the qualitative uptake and retention pattern 
in retina was similar after both modes of administration (Figure 39). This demonstrates a 
relatively low uptake in the healthy control eye, followed by rapid clearance, and a much higher 
uptake in the fellow I/R eye, and then sustained retention in the I/R eye. In fact, even the 
quantitative uptake/retention pattern was similar (with intravitreal administration showing a 30-
fold higher eye uptake, on an injected amount basis). Even though there is some choroidal 
presence of the intravenous dendrimer in normal eye, it appears to be mostly cleared within 72 
hours. Following intravenous administration, in the I/R eye, ~40% of the DCy5 uptake observed 
after 24 hours is retained up to 21 days. For intravitreal administration, ~16% of the D-Cy5 level 
from 24 hours is retained up to 21 days. 
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Figure 39: Quantification of dendrimer (D-Cy5) levels in posterior eye cups by fluorescence spectroscopy  (FLS) 
method. A) dendrimer levels in eye cups upon single intravitreal injection of 20µg of D-Cy5 showing significant 
difference in dendrimer uptake between non I/R and I/R eyes. B) dendrimer levels in eye cups upon single 
intravenous injection of 600µg of D-Cy5 via femoral vein. C) Comparison of dendrimer levels in I/R eyes in both 
intravitreal and intravenous administration routes showing not much significant differences. n=8, student t test. 
 
4.5. Discussions 
The current study demonstrates the ability of PAMAM dendrimers to target one key cell 
type in retinal neuroinflammation, activated microglia.  Retention by activated microglia 
occurred whether the dendrimer was delivered intravenously or intravitreally. Furthermore, the 
microglia retained dendrimer while other cell types did not take up the dendrimer. The 
dendrimers remained in microglia for an extended period of time, 21 days, the longest time point 
evaluated in this study. Activated microglia/macrophages have been associated with retinal 
diseases such as macular degeneration, diabetic retinopathy, glaucoma, and retinopathy of 
prematurity [151, 154-157]. Ischemia-reperfusion (I/R) injury has been used to model certain 
aspects of chronic glaucoma, diabetic retinopathy and branch vein occlusion (BVO). I/R injury 
causes occlusion of both retinal and choroidal blood vessels, resulting in reduced blood flow and 
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tissue hypoxia [152]. The above conditions were reported to cause disruption of blood retinal 
barriers (BRB) 152, 153], activation of resident microglia/macrophages, infiltration of microglia 
and macrophages from choroid and systemic circulation, elevated production of cytokines (TNF-
α, INF-α, TGF-β. IL-1β and IL-6) [154], and death of retinal ganglion cells (RGCs) [155]. 
Hydroxyl terminated generation 4 PAMAM dendrimers (G4-OH) conjugated with near 
IR dye Cy5 (D-Cy5) used in this study were well characterized in our previous study [150]. 1H 
NMR confirmed that one molecule of Cy5 was successfully conjugated to each dendrimer and it 
is sufficient to measure the amount of dendrimers at low levels of detection of 0.1ng. HPLC 
analysis demonstrated the high purity of D-Cy5 conjugates and successful synthesis. PAMAM 
dendrimer conjugated with fluorescent dyes we used in previous studies as diagnostic probes to 
investigate the biodistribution and cellular localization of dendrimers in central nervous system 
[156, 157]. We used cyanine Cy5 dye, which is near IR to avoid tissue auto-fluorescence from 
retinal cells, especially microglia and RPE cells. In order to investigate the biodistribution, 
dendrimer–retinal cell interactions, and differences in retinal distribution upon different mode of 
administration, we used both intravitreal and Intravenous route of delivery.    
Dendrimers after intravitreal and intravenous injection showed pathology-dependent 
retinal distribution. Upon intravitreal injection, dendrimers were mostly cleared from normal 
retina within 24 hrs, whereas in I/R retinas, they were found specifically localized in activated 
microglia (round or fusiform and Iba-1+) in INL, ONL and in near vicinity of ILM. This can be 
attributed to the increased phagocytic activity of activated microglial cells. Moreover free Cy5 
was not localized in Iba-1+ cells in I/R retina and were completely cleared after 24 hrs. Activated 
microglia. Macrophages were present at 72 hrs but appear to have migrated towards the 
photoreceptor layer. In normal retina, microglia is restricted to inner retinal layers but under 
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pathological conditions such as I/R injury exhibit dynamic behavior like migration to the injury 
site and engulfment of dead cells. In I/R injury there reported a ganglionic and photoreceptor cell 
death and RPE atrophy and accumulation of microglia in INL, ONL and subretinal space. At 21 
days post intravitrial injection in I/R eyes, dendrimers were still retained in microglia, but the 
amount of D-Cy5 had decreased compared to 24 and 72 hrs. This corresponded to a decline in 
the number of activated microglia and a return to their quiescent ramified morphology. Such 
changes in microglia morphology are in agreement with previous studies by Zhang et al. [153].      
Retina has a blood retinal barrier, so entry of dendrimers into retina in normal animals 
must be from the choroidal vasculature.  Although the capillary system of choroid has tight 
junctions, it also has fenestrations. It appears that the D-Cy5 in normal choroid must have 
traversed the fenestrations. However, after I/R injury, the retinal barriers are breached so 
systemic D-Cy5 passes through leaky retinal blood vessels and perhaps through injured RPE 
from choroid. As in intravitreal injection, activated microglia after injury take up the D-Cy5 and 
retain it for 21 days, the longest time point in this study  
It was striking that the majority of the D-Cy5 was cleared quickly from the body whether 
injected intravitreally or intravenously, yet activated microglia retained it. Clearance studies 
demonstrated that kidney and liver retained the largest percentage of the intravenous D-Cy5 
dose. All organs showed complete clearance of D-Cy5 by 72 hrs except kidney, which had a 
small 0.0008% uptake. This is clear evidence that D-Cy5 is cleared intact from the body after 
intravenous administration and only remains in cells spanning injured retina at 21 days. 
Clearance after intravitreal administration was visually apparent at 24 hrs (daa not shown, when 
the blue color of the D-Cy5 had disappeared from the normal globe. Furthermore, there was no 
indication of toxicity from the D-Cy5. 
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The ischemia reperfusion (I/R) model selected for these studies represents some aspects of 
branch vein occlusion.  It also represents a retinal injury in which there is hypoxia, then tissue 
injury, followed by activation of microglia. This I/R model causes cell death and an 
inflammatory response. This model was used in a study by Zhang et al to create a short term 
model of some events in diabetic retinopathy: creation of acellular capillaries, death of neurons, 
and increased vascular permeability.  They also demonstrated significant activation of microglia 
in the model [159]. In non-I/R retinas, microglia are ramified or quiescent but, following I/R, the 
cells are round or fusiform, indicating they are activated and phagocytosing . There were also 
less microglia in non-I/R retina compared to I/R retinas. 
 An important observation was that the D-Cy5 was retained almost exclusively in 
activated microglia, whether they were delivered intravenously or intravitreally. Intravenous 
administration is safer than intravitreal, but intravitreal is currently the standard of care for anti-
VEGF therapies used in treating exudative age-related macular degeneration (wet AMD) and 
diabetic macular edema. D-Cy5 retention in microglia at 21 days post femoral injection is also 
very significant in that repeated injections like current anti-VEGF therapies would not require 
intravitreal injection. Femoral administration of the dendrimer resulted in less Cy5 fluorescence 
in the retina than intravitreal administration but still a substantial number of microglia had D-
Cy5. Both intravitreal and intravenous non-I/R controls with D-Cy5 at 24 hours post activated 
injection showed no fluorescence of Cy5 indicating that the dendrimer was cleared from the eyes 
at 24 hours post administration; these healthy controls had no microglia. With intravenous 
administration it could be argued that D-Cy5 would not traverse the blood brain barriers. In I/R 
injury and in our cerebral palsy (CP) model, the blood barriers are compromised as part of the 
pathology, Cy5 alone administered intravenously or intravitreally was not localized to microglia. 
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This difference in distribution of unconjugated Cy5 proves that dendrimer retains its cargo and 
has a favorable distribution in diseased and healthy retina (retention and clearance respectfully). 
Furthermore, Cy5 was not ever present in microglia, indicating that it is the dendrimer that is 
targeted to activated microglia, not the dye. 
In chronic diseases like diabetes, microglia are activated in human diabetic retinopathy 
and undoubtedly they contribute to the neuroinflammation and death that occurs in diabetic 
retina. Because diabetic retinopathy is a chronic disease, it is not possible to repeatedly inject 
therapeutics intravitreally as this can lead to further damage to vision. With intravenous 
injections of dendrimer, repeated injections would be possible as this leads to no secondary 
damage to the eye. The retention of dendrimers in activated microglia cells at 21 days post 
intravenous injection indicated that drugs bound to dendrimers could be released slowly over a 
prolonged period of time decreasing the need for multiple injections in a short period of time.  
This is a great advantage as it decreases the need for regular PAMAM dendrimers 
because they target only activated microglia after intravenous administration. These attributes 
suggest that these dendrimers could be used to treat diabetic retinopathy where retinal blood 
vessels leak and retinal microglia are activated. Another potential target would be AMD where 
the outer retinal barrier is lost and activated microglia/macrophages are thought to contribute to 
the pathology. Kannan et al used dendrimers with N-acetyl cysteine (D-NAC) in a rabbit model 
of CP and observed attenuated activation of brain microglia and astrocytes. Kits treated with D-
NAC had an improved muscle tone from day 1 to 5 compared to kits treated with PBS 
(P<0.001).  
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Therefore, the current study demonstrates the potential for intravenous delivery to target 
activated microglia in retina and choroid in many inflammatory diseases in the eye. Attenuation 
of the microglia activation in AMD and diabetes would decrease the degeneration of 
photoreceptors and other neurons. The only therapies currently available require monthly 
intravitreal injections. If it is possible to give drugs systemically that can target the desired cells 
and release therapies slowly, injections will be needed less frequently and the complications of 
injections into the eye will not occur. 
4.6. Conclusions: 
We investigated the retinal biodistribution of dendrimers, upon intravitreal and systemic 
administration, in a mouse model where one eye was healthy and the other eye had I/R injury. 
The qualitative biodistribution was somewhat similar after intravitreal and systemic 
administration of the dendrimer after I/R injury. There was a differential retinal biodistribution of 
dendrimers between the healthy eye, and the injured fellow eye, with D-Cy5 localizing 
selectively in activated microglia/macrophages in the injured eye. Once localized in activated 
microglia, the dendrimers appeared to be retained to an appreciable extent, up to 21 days. The 
ability of the dendrimer to selectively target activated microglia, even upon systemic 
administration may offer significant opportunities for targeted, sustained, systemic therapies for  
retinal degeneration. The relatively rapid clearance of the dendrimers from the healthy eye, and 
off-target organs suggests that dendrimers may reduce side effects associated with current ocular 
drugs. 
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CHAPTER 5 “IN-VIVO EVALUATION AND EFFICACY OF THE PREPARED 
DENDRIMER DRUG CONJUGATES IN RAT MODEL OF CNV” 
5.1. Abstract 
Choroidal neovascularization (CNV) is a major complication of age-related macular 
degeneration (AMD) resulting in devastating damage to the retina. Increasing evidence suggests 
microglia/macrophages may play a critical role in the development and the progression of AMD. 
When injected, polyamidoamine (PAMAM) dendrimers have been shown to be taken up in 
activated microglial cells in brain and retina in response to inflammatory stimuli. The purpose of 
this study was to investigate whether intravenously injected dendrimers would accumulate and 
deliver drugs in a lipid-induced CNV rat model. Dendrimer-Cy5 (D-Cy5) and dendrimer-N-
acetyl-L-cysteine (D-NAC) conjugates were evaluated in lipid-induced rat CNV model. A single 
dose of D NAC+D-Cy5 was administered intravenously on day 3 post lipid injection. Rats 
injected with D-Cy5 alone and PBS served as controls. Rats were sacrificed 7 days post 
dendrimer injections, and then retina and choroids were prepared for flat mount IHC. Flat-
mounts were imaged under Zeiss 710 confocal microscope. The co localization of D-Cy5 was 
assessed using IBA-1 antibody (macrophage/microglia) and GSA lectin-FITC (blood vessels and 
microglia). The CNV areas and the microglial counts in the CNV and RNV areas were assessed. 
Sub-retinal lipid injection stimulated the migration of IBA-1 positive microglial/macrophages 
and formation of CNV. Intravenous administration of D-Cy5 was colocalized predominantly in 
activated microglia/macrophages in the CNV/RNV areas. Image analysis showed that D-
NAC+D-Cy5 treated rats had a ~30% reduction in the CNV area and a significant reduction in 
microglial cell counts associated with the CNV/RNV compared to controls, following just one 
dose of D-NAC. D-Cy5 was selectively taken up by activated microglia/macrophage cells and, 
therefore, is promising for delivering anti-inflammatory drugs to retina/choroid via systemic 
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administration. The efficacy of D-NAC in reduction of microglia numbers and CNV regression 
opens a new therapeutic window for delivering a combination of intravenous anti-angiogenic and 
anti-inflammatory drugs as an effective treatment option for early stages of AMD and perhaps 
other ocular inflammatory diseases. 
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5.2. Introduction 
Age related macular degeneration (AMD) is one of the leading causes of blindness in the 
western world often affected in individuals between 65 and 75 years of age [160]. AMD causes 
decline in central vision due to the photoreceptor loss in the macular area. This photoreceptor 
atrophy is often result of accumulation of drusen (lipid and photoreceptor fragments accumulated 
in the subretinal layer) (dry form) leading to onset pathological events. The slow progression of 
events includes neuroinflammation, microglial & monocyte accumulation and infiltration, 
increased production cytokines, growth factors such as HIF-1 &2, VEGF 1 & 2 and etc. causing 
formation of new blood vessels leading to neovascularization and disruption of blood retinal 
barrier resulting in decline of retinal homeostasis [161]. Inflammation, mediated by activated 
microglia/macrophages, plays a key role pathogenesis of neovascularization and multiple early 
disease alterations involving retinal pigment epithelium and photoreceptor atrophies. It has been 
reported in many previous research studies that resident microglia have primary responsible in 
clearing up the accumulated drusen by phagocytosis and there by digesting them and hence 
avoiding toxic effects [162].  Under overwhelming circumstances of continuous pathological 
stimulation these resident microglial cells become activated to pro-inflammatory cells 
completely changing their function causing devastating effects [163]. Activated microglial cells 
have multiple effects such as increased production of cytokines, angiogenesis growth factors and 
chemokine for macrophage infiltration from systemic circulation, oxidative stress and 
endothelial dysfunction [164]. Current treatment options for AMD are intravitreal injections of 
antiVEGF agents, monoclonal antibodies such as pegatanib, bevabizumab, ranibizumab and 
vitriprofin. The above therapies are effective only for short term and repeated injections are 
required and often have severe side effects [165]. Focus towards attenuating neuroinflammation 
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and neovascularization as a combined treatment option will be beneficial. A drug delivery 
system that can target choroid and retina neovascularization upon systemic delivery via 
intravenous route achieves patience compliance and avoids the incidence of intraocular 
infections. 
Polyamidoamine (PAMAM) dendrimers have been shown to localize in cells associated 
with neuroinflammation. Dendrimer-drug conjugates showed significant efficacies in retinal 
degeneration models upon intravitreal delivery, and in cerebral palsy model upon intravenous 
delivery. NAC is used as an antioxidant agent in various disease conditions such as 
photoreceptor dystrophies, CNV and AMD [161]. NAC is proved to have protective effects and 
facilitates long-term survival of cone photoreceptors which are responsible for central and clear 
vision [161]. NAC is required to be delivered at high concentrations in order to achieve a 
therapeutic efficacy because of its low stability and clearance. Moreover it causes retinal toxicity 
and ganglionic atrophy. Dendrimer N-Acetyl cysteine conjugates (D-NAC) have been reported 
to attenuate neuroinflammation in cerebral palsy rabbit model and improves motor function in 
rabbit pups.    
Triamcinolone acetonide (TA) is a potent angiostatic steroid, which can exert multi-
pronged effects on many complications of AMD, including neuroprotective and anti-angiogenic 
properties[166-172]. It has shown promise against CNV in multiple animal models [171, 172]. 
TA has been used clinically in combination with other approaches, mostly as an intravitreal 
formulation, for diabetic macular edema (DME), retinal vein occlusion, and some forms of AMD 
[171] The side effects associated with intravitreal TA include elevated intra-ocular pressure and 
cataract [173]. 
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In chapter 2, we have shown that dendrimer-triamcinolone conjugates (D-TA) show 
sustained anti-inflammatory and anti-VEGF activity in activated microglia and hypoxic retinal 
pigment epithelium. D-TA has overcome the solubility issue and was better in terms of efficacy 
at 100 fold lower concentration that free drug. The above studies indicate that D-TA treatment 
will overcome the toxicity and elevated IOP. Chapter 4 results suggest that upon intravenous 
injection dendrimers can target activated microglial cells and RPE, indicating their intrinsic 
targeting ability. By combining the targeting ability of dendrimers and using dendrimers as drug 
carriers for two above mentioned drugs (NAC and TA) as a potential treatment option fpr 
intravenous therapies for AMD. 
In this chapter, we evaluate the efficacy of dendrimer-N-Acetyl cysteine conjugates (D-
NAC) as an intravenous treatment option for treating early AMD stages (dry AMD) and a 
combination therapy (D-NAC + D-TA) as a treatment option for late stages of AMD (wet AMD 
with CNV) via intravenous route. Upon systemic administration, dendrimer crosses blood retinal 
barrier (BRB) and accumulated only in the activated microglia/macrophage of choroids and 
retina. Moreover, D-NAC and D-TA treatments both individually and combined resulted in 
significant reduction in choroidal and retinal inflammation by decreasing the 
microglia/macrophage accumulation in CNV areas. In the case of CNV growth the dendrimer 
formulations suppressed significantly whereas, the free drug did not show significant reduction 
in microglia/macrophage accumulation and CNV suppression. Upon further evaluation of these 
conjugates for various parameters may result in profound insights that can be helpful in 
developing dendrimer based delivery of various different drugs via intravenous rout as an 
effective and potential treatment option for treating various retinal diseases such as AMD, CNV, 
diabetic retinopathy and etc. 
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5.3. Materials and methods 
5.3.1. Synthesis & characterization of Dendrimer-NAC conjugates (D-NAC) 
Dendrimer-NAC (D-NAC) conjugates were synthesized using 4 steps protection and 
deprotection reactions. In the 1st step G4-OH is reacted with Fmoc-GABA acid using PyBOP as 
coupling agent in the presence of DIEA as base. The resultant bifunctional dendrimer is 
deprotected using pypridine to obtain bifunctional dendrimer with amine groups.  In the 3rd step 
the amine groups were reacted with SPDP for 6hrs and NAC is added to get D-NAC. The 
conjugates were purified and characterized using 1H NMR, and HPLC for purity and drug 
loading.  
5.3.2. HPLC analysis of D-NAC conjugates 
The purified dendrimer NAC conjugate (D-NAC) was analyzed by Waters HPLC 
instrument (Waters Corporation, Milford, Massachusetts) equipped with binary pump, 
photodiode array (PDI) detector, and auto sampler interfaced with Empower software. The 
HPLC chromatogram was monitored at 210 and 205 nm simultaneously using PDI detector. The 
water/acetonitrile (0.1% w/w TFA) was freshly prepared, filtered, degassed, and used as a 
mobile phase. Symmetry C-18 reverse phase column with 5 μm particle size, 25 cm length, 4.6 
mm internal diameter was used. A gradient flow was used with initial condition of 100:0 
(H2O/ACN) and gradually increasing the gradient condition of 90:10 (H2O/CAN) till 10min to 
50:50 (H2O/ACN) in 20 min and returning to 100:0 (H2O/ACN) in 40 min with flow rate of 1 
mL/min.  
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5.3.3. Animals and CNV model 
In this study, male Sprague-Dawley rats from Harlan Laboratories Inc. (Frederick, MD) 
were used.  The ages of the animals were between 6-8 weeks and they each weighed 
approximately 200-250 g. The animals were housed in the Johns Hopkins Animal facility and all 
animal care and experimental procedures complied with the Association for Research in Vision 
and Ophthalmology (ARVO) statement for the Use of Animals in Ophthalmic and Vision 
Research and the Johns Hopkins University guidelines for Care and Use of Laboratory Animals. 
Rat CNV model is established in Dr. Gerard lutty’s Lab at Wilmer eye institute, Johns 
Hopkins University. Briefly, HpODE (lipofuscin extracted from human AMD patients) were 
dissolved in sterile borate buffer at a concentration of 20µg/2µL. SD rats of 8 weeks age and 
~250grams of weight were chosen and anesztied using ketamine (100mg/Kg) and Xylazine 
(10mg/Kg) injected into the peritoneal space. 2µL of HpODE solution was given as subretinal 
injection using nano-injector and glass needle. Bleb formation is confirmed upon injection using 
an optical microscope funds examination. HpODE injection causes inflammation resulting in 
accumulation of inflammatory resident choroidal and retinal microglia in and around the bleb 
area, retinal thinning, RPE dystrophy, and choroidal and neovascularization [61]. 
5.3.4. Dendrimer conjugates injections: 
For biodistribution studies, 6mg of Cy5 labelled conjugates (D-Cy5) (20 mg/Kg on 
dendrimer basis) were injected intravenously via penile vein. Linear polymer dextran-FITC (Mol 
wt 15,000 daltons) (Sigma-Aldrich) and 20 nm polystyrene nanoparticles (red nanoparticles, Cy3 
wavelength) were injected on equimolar basis same as D-Cy5.  For efficacy studies D-NAC 
(20mg/Kg on NAC basis) were injected intravenously on day 3, 5 and 7 for early AMD 
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treatment and sacrificed on day 10. For late AMD treatment, the animals were not treated until 
day 9 but on day 10, a combination therapy of D-NAC (20 mg/Kg on NAC basis) and D-TA 
(10mg/Kg on TA basis) were dissolved together in 300 µL of PBS and injected intravenously on 
day 10, 13 and 15 and on day 19 the were sacrificed with an overdose of sodium pentobarbital 
(50mg/ml) intraperitoneally. The eyes were enucleated immediately and placed in distilled water 
with 1X Tris-buffered saline (TBS) (pH 7.4). 
5.3.5. Tissue Processing and Immunohistochemistry 
 After one hour on wet ice to allow for post-mortem time, using a micro-dissection 
vannas scissors the anterior segment was removed using a circumferential cut near ora serrata.  
the anterior segment of the eye was removed and the retina was separated from the choroid. The 
retina and choroid with retinal pigment epithelial (RPE) cells and sclera attached were fixed for 
24 hours at 4°C, in 2% paraformaldehyde in 0.1 mol/L cacodylate buffer, pH 7.4. The next day, 
the tissue was washed in 1XTBS for 30 minutes. Both retina and choroid were blocked for 6 
hours at 4°C using 5% normal goat serum (Jackson ImmunoResearch, PA) in 1XTBS, 1% 
bovine serum albumin (BSA) and 0.1% Triton X-100 (Sigma Aldrich, MO). After the tissue was 
washed for 10 minutes at 4°C in 1XTBS with 0.1% Triton, it was incubated with the primary 
antibody Anti-IBA1, Rabbit (1:500, Wako Pure Chemicals, Japan) in 1XTBS, 1% BSA and 
0.1% Triton, for 20 hours at 4°C. The next day, the tissue was washed in 1XTBS with 0.1% 
Triton for 30 minutes at 4°C and the secondary antibodies Goat anti-Rabbit Cy3 (1:200, Jackson 
ImmunoResearch, PA) and Isolectin GS-IB4 AF488 (1:100, Thermo Fisher, MA)were applied to 
the tissue and incubated for a further 20 hours at 4°C. After application of antibodies, all tissue 
was washed for 30 minutes in 1XTBS at 4°C. 
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5.3.6. Choroidal and Retinal flatmounts imaging by confocal microscopy: 
Choroid & retinal flat mounts were performed on glass slides. To make them flat 3 to 4 
relaxing radial cuts are performed using vannas scissors and the flattening was stabilized using 
micro slide cover slips. The flat mounts were imaged under Zeiss 710 confocal microscope. 3 
channels are used Cy3 channel for Iba-1, FITC 488 channel for lectin blood vessels and Cy5 
channel for D-Cy5. Choroids flat mounts were imaged at 5X magnification, Tiled Scan of 9X9 
with overlap 10%. The images showed here are collapsed; tile stitched using Zen confocal 
software.  Retinal flat mounts were imaged at 20X magnification, 6X6 tiled Z scan with overlap 
10%. The images shown here are collapsed; tile stitched using Zen confocal software. 
5.3.7. Image analysis and cell counting and morphology analysis 
CNV areas were analyzed using Image-J software morphometric analysis. Choroidal 
whole mount images were magnified 20 times using magnifier option and using a digital pen the 
CNV borders were delineated and using area analysis. Macrophage/microglial counts in choroid 
and retina were performed using Imaris software. Three areas of interest (3x3 tile zone) were 
chosen from the bleb area and the cell count analysis were done using Imaris (Bitplane) software 
using surface function with smoothing factor and cell size threshold of 8-12 µm diameter with 
split function. Activated and resting microglia in retinas was counted based on cell shape using 
cell surface function. The function ‘surfaces’ was used and the individual Iba1+ 
microglia/macrophages were analyzed for surface and volume of each cell in bleb area and area 
away from the bleb, approximately 150 cells were included for each region. The threshold 
settings were based on the diameter of cells, cell surface to volume ratio with sphericity of 0.758 
add ellipiticity function 0.298 as threshold. 
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5.3.8. RT-PCR analysis of cytokines in retina and choroids 
The retinas and choroid of  rats were collected at day 10 post D-NAC treatment to 
evaluate the mRNA levels using quantitative RT-PCR (qRT-PCR). Total mRNA was extracted 
using triZol for cDNA synthesis (SuperScript III First-Strand Synthesis SuperMix, Invitrogen, 
CA, USA). The procedures of mRNA extraction and cDNA synthesis followed those provided 
by the manufacturers and the primers are listed in Table 3. Reactions were performed in a 25 µL 
eppendorf tube with 2 µL of cDNA, 0.3 ml of forward and reverse primer (10 pmol/µL), 10 µL 
of 26Mix (full velocity SYBR greenqPCR master mix, Stratagene) Taq and 7.4 ml of ddH2O. 
The procedure for real-time qRT-PCR included 5 min at 99ºC, followed by 40 cycles of 15 s at 
94ºC, 30 s at 59ºC, and 45 s at 72ºC (Roche LC480, Roche Applied Science). All the qRT-PCR 
reactions were run in triplicate to yield averaged Ct values. Expression (evaluated as fold change 
for each target gene) was normalized to GAPDH. 
 5.4. Results and discussions 
5.4.1. Synthesis and Characterization of D-NAC conjugates 
  D-NAC was synthesized using 4 step reaction process. Bifunctional dendrimer was 
synthesized using FMOC protection and de-protection resulted in 21 primary amine groups on 
the dendrimer surface (1H NMR analysis). These amine groups were reacted with SPDP, a 
bifunctional linker which has NHS ester on one side and PDP group for disulfide bonds on other 
side. The NHS group reacts with amine group to form an amide bond. This reaction will be 
completed by stirring them at nitrogen atmosphere overnight and NAC was added. The PDP 
group will react with thiol (SH) group of NAC to for disulfide bond that is cleavable only in 
intracellular glutathione levels. 
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1H NMR analysis confirms 18 molecules of NAC were conjugated to each dendrimer which 
corresponds to 20% of the payload. HPLC analysis confirms the purity and successful 
completion of the reaction and devoid of small molecule and side products impurities. A release 
experiment was carried out in PBS with different varying concentrations of glutathione ranging 
from plasma concentrations (2µM) to intracellular concentrations in microglial cells (500µM). 
The conjugates released NAC on increased glutathione levels where as significantly low amount 
was released in extracellular plasma glutathione levels. On other hand the conjugates released 
NAC almost ~60% of payload within 2hrs.  
5.4.2. CNV formation induced by subretinal injection of HpODE  
Blood vessel vasculature was observed by confocal microscopy using GS Isolectin (red) 
in flat-mounted choroids 10 days after borate or HpODE injection. Rats injected with borate 
only, did not show development of CNV in the bleb site or in the surrounding area of the choroid 
(Figure 40A). A higher magnification of the bleb area with GS Isolectin (red) only, does not 
show CNV formation, however there appears to be some degeneration of the chorio-capillaris 
(CC) in the bleb area (Figure 40E). The mean CNV area of borate injected eyes was 0 mm2. In 
contrast, HpODE injected rats showed distinct formation of CNV in the bleb area (Figure 40B). 
In all cases of HpODE injected eyes, CNV formation was present with a high area of CC 
degeneration in the bleb area (Figure 40F). The mean CNV area of HpODE injected eyes was 
0.24±1.64 mm2. Statistical analysis shows a significant difference between the CNV areas of 
HpODE compared to borate injected rats (P<0.0001). Interestingly, there was onset of microglial 
accumulation in the bleb area and around the CNV.  
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5.4.3. Biodistribution of dendrimers in choroid and retina 
Delivering drug to targeted cells is critical and important in-order to have significant 
efficacy. We used model dendrimer conjugates, D-Cy5 as a marker to know the targeting 
capability and delivery of drug to the retina and choroid upon intravenous injection. D-Cy5 was 
injected via penile vein and ocular biodistribution was investigated using flat-mount imaging. 
Seven days post injection flat-mounts of choroid and retina were imaged using 710 confocal 
microscopy. D-Cy5 were found accumulated in microglia/macrophages in the choroid bleb area 
~80.25% (Figure 42) of total microglial cells in the bleb area were activated [based on their 
shape (amoeboid, elliptical and circular with short and few dendrite process)] and almost all of 
the activated population of microglia/macrophages were uptake with dendrimers (red signal, 
Figure 41A). Such specific co-localization of dendrimers in microglia/macrophages suggests 
that intravenous therapies for targeting ocular inflammation are possible. The specific 
localization and retention of dendrimers both in retinal and choroidal activated macrophages can 
be attributed to its size, shape and phagocytic activity microglia/macrophages when activated.  
To understand the influence of shape and size; we used a linear dextran molecule and a 
larger nanoparticle polystyrene 20 nm particles to compare and to know if the same fashion of 
biodistribution is observed. Interestingly, in the case of linear dextran, did not exhibit such 
pathology dependent biodistribution. Moreover, dextran was found in only in large retinal blood 
vessels and did not get co-localized in activated microglia/macrophages. In the case of 20 nm 
polystyrene nanoparticles did not show any sign of retention and seemed to be excreted, 
suggesting the influence of size and shape of the dendrimers. 
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Figure 40: Flat mount images of choroids representing the changes and CNV growth after subretinal HpODE 
injections A) Borate injected choroid showing no CNV formation whereas B) HpODE injection showing formation 
of CNV (white arrow) and microglial/macrophage accumulation (green). The CNV formed is indicated by arrow in 
panel F (red). Scale bar 100µm. 
 
 
Figure 41: A) Choroidal flat mounts from lipid-injected eyes, imaged 7 days after D-Cy5 (red) administration (Day 
10), stained for blood vessels (isolectin), macrophages (IBA-1, green). The D-Cy5 localizes in the IBA-1 
macrophages. Minimal D-Cy5 uptake is seen in the IBA-1 labeled ‘ramified’ macrophages in healthy choroids. See 
Figure 7 later. Scale bar is 100µm B) Retinal flatmounts depicting microglial migration and accumulation in the bleb 
area corresponding to choroid with dendrimer co-localization and retention in activated microglia. 
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5.4.4. D-NAC treatment suppresses CNV in early AMD period 
D-NAC was administered on Day 3 (two days after lipid administration), and on day 5 
and day 7 at 20 mg/kg on a NAC basis. D-NAC caused significant suppression of CNV when 
assessed on Day 10 compared to free NAC at equivalent doses, and untreated controls (PBS 
injected). Untreated controls have irregular choriocapillaries that are enlarged with outgrown 
blood vessels. The mean area of CNV in untreated choroids were 0.24±1.64 mm2, and D-NAC 
treated choroids showed significant reduction in CNV area 0.08±2.43 mm2 which corresponds to 
~78% suppression (Figure 42A & B). Free NAC treatment showed little reduction of CNV but 
not significant than compared to D-NAC treatment. The CNV suppression after D-NAC 
treatment is in good agreement with biodistribution studies where dendrimers were found 
localized and retained in activated microglial cells suggesting that D-NAC delivers NAC to the 
inflammatory cells in the area of pathology. 
 
Figure 42. Effect of intravenous injections of  free NAC, D-NAC or PBS, on CNV. D-NAC treated animals showed 
significant decrease in CNV areas when compared to PBS. Free NAC showed some decrease that was not 
significant. CNV areas were assessed using morphometric analysis (yellow delineation) in Image-J software. Panel 
A shows the PBS choroid with larger CNV and increased population of macrophages (green) in the bleb area, 
whereas panel B shows the efficacy of D-NAC with reduced CNV and macrophage accumulation. The vasculature 
was stained with GSA lectin (blue), and macrophages are stained with IBA-1 (Green). 
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5.4.5. D-NAC treatment reduces macrophage migration and accumulation to CNV area 
The extent of macrophage depletion in the CNV region, upon systemic D-NAC therapy at 
20 mg/kg NAC was assessed on Day 10, using IBA-1 staining. A significant reduction in total 
macrophages accumulation (~63%) was seen upon D-NAC therapy. Previous studies by Ambati 
and coworkers showed that macrophage depletion correlated with CNV reduction [174]. 
Interestingly, morphological analysis using Imaris [175] suggested that there was a 80% 
reduction in activated macrophages, and ~90% of the these activated macrophages contained D-
Cy5 (in both PBS and D-NAC treated animals), indicating selectivity (Figure 43C).  
 
Figure 43: Flat mount image analysis of choroids for macrophage accumulation in the bleb area surrounding the 
CNV. Macrophages were stained with IBA-1 (Green) and D-Cy5 is red. Macrophage cell count analysis showed a 
~63% reduction in number of macrophages cells, and a ~60% reduction in activated macrophages upon D-NAC 
compared to PBS treatment, with near 90%+ colocalization of activated macrophages and dendrimers. The cell 
count analysis was done using Imaris (Bitplane) software. 
 
5.4.6. D-NAC treatment suppressed choroidal and retinal inflammation 
The effect of D-NAC treatment on choroidal and retinal inflammation was accessed using 
RT-PCR, by measuring proinflammatory (IL-1β, IL-6, MCP-1-monocyte chemo-attractant, and 
TNFα) and anti-inflammatory cytokine levels (IL-10) [167-178]. There was a significant 
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reduction in all the proinflammatory cytokines, which returned to levels seen in healthy controls, 
whereas free NAC was not effective (Figure 43A,B,D & E). This can be attributed to reduced 
microglial/macrophage accumulation in bleb area of choroid and retina, suggesting the 
suppression of inflammation and neovascularization. Interestingly, D-NAC appeared to enhance 
the anti-inflammatory cytokine IL-10 both in retina and choroid (Figure 44C & F). This 
suggests that selective attenuation of proinflammatory response can be achieved with D-NAC. 
 
Figure 44:  RT-PCR analysis of inflammatory and anti-inflammatory cytokines in choroid (A-C) and retina 
(D-F). The choroids and retinas of free NAC, D-NAC and PBS treated rats were subjected to trizol treatment and 
RNA was extracted and subjected to RT-PCR analysis. The expression was compared to healthy control with not 
pathology and relative to GAPDH.   
 
 
Similar to the biodistribution pattern seen in the CNV area, the D-Cy5 localized 
selectively in the activated microglia/macrophages in the bleb area (Figure 45B), but did not 
localize in the unaffected areas of the same retina (Figure 45A). In D-NAC treated retina, there 
was a reduction in the number of microglia/macrophages in the bleb area, and which were more 
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ramified with less D-Cy5 uptake. Suggesting that D-Cy5 treatment reversed activated microglia 
to resting and ramified microglia (Figure 45C).  
 
Figure 45: Flat mount retinas (40X magnification) with GSA-stained blood vessels,  IBA-1 for mi/ma, and 
dendrimer (D-Cy5); A) ‘Healthy’, non pathlologic area of same retina with regular blood vessel structure and resting 
mi/ma (ramified) (white arrows), and no D-Cy5; B) Pathological  area of the same retina near the bleb showing 
abnormal vessels, activated mi/ma (‘round’ and amoeboid)  and ‘spiked’ dendrimers co-localized in activated mi/ma 
(white arrows); C) D-NAC treated retina showing both populations (i) resting microglia (ramified) (yellow arrows) 
and (ii) activated mi/ma (amoeboid) with dendrimer (white arrows) suggesting the therapeutic effect of D-NAC in 
quieting microglial activation. 
 
 
5.4.7 A combination therapy of D-NAC and D-TA promotes CNV regressing in later stages 
of AMD. 
A combination of D-NAC (20 mg/kg on NAC basis) and D-TA (10 mg/kg on TA basis) 
was administered systemically at a later stage (on Day 11, Day 13 and Day 15) to assess the 
efficacy when significant CNV has already occurred: (1) On Day 19, there was a 72% reduction 
in CNV in dendrimer-treated animals, compared to PBS controls, suggesting that late treatment 
is effective (Figure 46); (2) Compared to the extent of CNV area on Day 10, there was a ~45% 
reduction in dendrimer-treated animals on Day 19, showing strong suggestions of CNV 
regression. These results (n=6) suggests that, significant CNV suppression may be possible with 
systemic therapies delivered with dendrimers. In this CNV model the time period from day 10 to 
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day 20 the formed CNV grows with larger blood, leaky and irregular blood vessels and are 
entirely different from regular choriocapillaries (Figure 47). A combination of anti-
inflammatory and anti-oxidant formulation (D-NAC) and an anti-angiogenic and anti-VEGF 
formulation (D-TA) treatment resulted in suppression of CNV growth further and regression. 
Regression can be attributed to the effect of TA delivered to microglia and RPE cells. D-NAC 
targets activated microglial cells and attenuate inflammation both in choroid and retina. A 
combine effect of D-NAC and D-TA may be necessary for treating late AMD where the CNV 
progress to retina forming retinal neovascularization (RNV) thereby, affecting the normal 
function retina, retinal and intravitreal hemorrhage. 
 
Figure 46: CNV area analysis of D-NAC + D-TA treated choroids showing significant regression (~52%) than 
compared to PBS treated choroids. At day 19 the PBS treated choroids showed significantly larger area 
neovascularization. ** indicates p<0.01. Scale bar at 100 µm. 
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Figure 47: Confocal images of CNV in choroid, the blood vessels are stained using lectin (blue) and the CNV 
borders are delineated using Image-J software (yellow lines). Representative images showing CNV of PBS-Day 
21(A), and PBS-Day 10(B),  and D-NAC+D-TA-Day 21(C). ** indicates p<0.01. Scale bar at 100 µm. 
 
 
5.5. Conclusions: 
This study has demonstrated for the first time that D-NAC and D-TA administered 
intravenously can drastically reduce CNV formation in an HpODE induced CNV rat model. At 
early stages of AMD (combination of lipid accumulation and growth of CNV) it was 
demonstrated by D-NAC treated eyes having a minute amount of CNV formation compared to 
HpODE control eyes that had obvious CNV growth. A very important observation is that the 
microglial accumulation and activation was significantly reduced in D-NAC treated retina 
choroids strongly suggesting that targeting inflammation may have impact on CNV growth.  At 
later stages of AMD a combination therapy of D-NAC and D-TA showed significant effect in 
promoting CNV regression and attention of inflammation by reversing the microglial 
conformation to resting stage. There was no increase in IOP levels or cataract formation after 
combination therapy making this an extremely promising therapy for wet AMD. Targeted 
therapy using dendrimers would mean that wet AMD patients can avoid invasive treatments such 
as intravitreal injections which would increase patient compliance. The long retention time of 
dendrimers in microglia/macrophages may also suggest less frequent treatments needed, 
therefore lowering the number of hospital trips needed and further reducing healthcare costs. In 
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future studies, it would be appropriate to vary the number of injections given, to vary the dosage 
of D-TA and to study animals for a longer period after HpODE injection, to ensure that treatment 
is effective for different stages of CNV development. Furthermore, D-TA and D-NAC toxicity 
should be carefully studied in addition to further experiments analyzing the mechanism of action 
of D-TA on retinal and choroidal endothelial cells (expression of ICAM and PCAM) and retinal 
blood vessel leakage. Nevertheless, this study has contributed to the advancement of medicine by 
demonstrating the potential therapeutic benefits of an intravenous dendrimer-based therapy for 
wet AMD. 
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 PAMAM dendrimers are a class of well-defined, hyperbranched polymeric nanocarriers 
that are being investigated for ocular drug and gene delivery. Their favorable properties such as 
small size, multivalency and water solubility can provide significant opportunities for many 
biologically unstable drugs and allows potentially favorable ocular biodistribution. This work 
exploits hydroxyl terminated dendrimers (G4-OH) as drug/gene delivery vehicles that can target 
retinal microglia and pigment epithelium via systemic delivery with improved efficacy at much 
lower concentrations without any side effects.   
Two different drugs Triamcinolone acetonide (TA) and N-Acetyl Cysteine (NAC) 
conjugated to G4-OH dendrimers showed tailorable sustained release in physiological relevant 
solutions and were evaluated in-vitro and in-vivo. Dendrimer-TA conjugates enhanced the 
solubility of TA and were 100 fold more effective at lower concentrations than free TA in its 
anti-inflammatory activity in activated microglia and in suppressing VEGF production in 
hypoxic RPE cells. Dendrimers targeted activated microglia/macrophages and RPE and retained 
for a period of 21 days in I/R mice model. The relative retention of intravitreal and intravenous 
dendrimers was comparable, if a 30-fold intravenous dose is used; suggesting intravenous route 
targeting retinal diseases are possible with dendrimers. D-NAC when injected intravenously 
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attenuated retinal and choroidal inflammation, significantly reduced (~73%) CNV growth at 
early stage of AMD in rat model of CNV. A combination therapy of D-NAC + D-TA 
significantly suppressed microglial activation and promoted CNV regression in late stages of 
AMD without causing side-effects.     
G4-OH was modified with linker having minimal amine groups and incorporation of TA 
as a nuclear localization enhancer resulted in compact gene vectors with favorable safety profile 
and achieved high levels of transgene expression in hard to transfect human retinal pigment 
epithelial cells (hRPE). Prepared dendrimer-gene complexes were non-toxic and achieved 
significant cell uptake and safe delivery of gene in to the nucleus. Further, polyethylene glycol 
(PEG) surface coating enhanced colloidal stability in physiological relevant solutions without 
affecting its transfection efficacy.  
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